-- =====================================================================================
-- TIER 4: CYP3A4/CYP2D6 METABOLIC INTERACTION MATRIX
-- Generated: 2026-01-16T07:03:04.488170
-- DDI Count: 2816
-- Generator: KB-5 DDI Matrix Generator Pipeline
-- =====================================================================================

BEGIN;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-simvastatin', 'ketoconazole_cyp', 'Ketoconazole', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lovastatin', 'ketoconazole_cyp', 'Ketoconazole', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-midazolam', 'ketoconazole_cyp', 'Ketoconazole', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-triazolam', 'ketoconazole_cyp', 'Ketoconazole', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-tacrolimus', 'ketoconazole_cyp', 'Ketoconazole', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-sirolimus', 'ketoconazole_cyp', 'Ketoconazole', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-temsirolimus', 'ketoconazole_cyp', 'Ketoconazole', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-oxycodone', 'ketoconazole_cyp', 'Ketoconazole', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-sufentanil', 'ketoconazole_cyp', 'Ketoconazole', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-methadone_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-sildenafil', 'ketoconazole_cyp', 'Ketoconazole', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-tadalafil', 'ketoconazole_cyp', 'Ketoconazole', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-vardenafil', 'ketoconazole_cyp', 'Ketoconazole', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-nifedipine', 'ketoconazole_cyp', 'Ketoconazole', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-nisoldipine', 'ketoconazole_cyp', 'Ketoconazole', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-nimodipine', 'ketoconazole_cyp', 'Ketoconazole', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lercanidipine', 'ketoconazole_cyp', 'Ketoconazole', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-ticagrelor_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-rivaroxaban_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-nilotinib_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lapatinib_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-palbociclib', 'ketoconazole_cyp', 'Ketoconazole', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-venetoclax', 'ketoconazole_cyp', 'Ketoconazole', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-olaparib', 'ketoconazole_cyp', 'Ketoconazole', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-ruxolitinib', 'ketoconazole_cyp', 'Ketoconazole', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-paclitaxel', 'ketoconazole_cyp', 'Ketoconazole', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-vincristine', 'ketoconazole_cyp', 'Ketoconazole', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-vinblastine', 'ketoconazole_cyp', 'Ketoconazole', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-maraviroc', 'ketoconazole_cyp', 'Ketoconazole', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lopinavir', 'ketoconazole_cyp', 'Ketoconazole', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-saquinavir', 'ketoconazole_cyp', 'Ketoconazole', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-quetiapine_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lurasidone_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-ziprasidone_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-trazodone_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-vilazodone', 'ketoconazole_cyp', 'Ketoconazole', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-tiagabine', 'ketoconazole_cyp', 'Ketoconazole', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-zonisamide', 'ketoconazole_cyp', 'Ketoconazole', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-zolpidem_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-zaleplon', 'ketoconazole_cyp', 'Ketoconazole', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-suvorexant', 'ketoconazole_cyp', 'Ketoconazole', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-lemborexant', 'ketoconazole_cyp', 'Ketoconazole', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-methylprednisolone', 'ketoconazole_cyp', 'Ketoconazole', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-quinidine_3a4', 'ketoconazole_cyp', 'Ketoconazole', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-tamsulosin', 'ketoconazole_cyp', 'Ketoconazole', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ketoconazole_cyp-tolvaptan', 'ketoconazole_cyp', 'Ketoconazole', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-ketoconazole_cyp', 'ketoconazole_cyp', 'Ketoconazole', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ketoconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ketoconazole and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ketoconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-simvastatin', 'itraconazole_cyp', 'Itraconazole', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lovastatin', 'itraconazole_cyp', 'Itraconazole', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-midazolam', 'itraconazole_cyp', 'Itraconazole', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-triazolam', 'itraconazole_cyp', 'Itraconazole', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-tacrolimus', 'itraconazole_cyp', 'Itraconazole', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-sirolimus', 'itraconazole_cyp', 'Itraconazole', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-temsirolimus', 'itraconazole_cyp', 'Itraconazole', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-oxycodone', 'itraconazole_cyp', 'Itraconazole', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-sufentanil', 'itraconazole_cyp', 'Itraconazole', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-methadone_3a4', 'itraconazole_cyp', 'Itraconazole', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-sildenafil', 'itraconazole_cyp', 'Itraconazole', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-tadalafil', 'itraconazole_cyp', 'Itraconazole', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-vardenafil', 'itraconazole_cyp', 'Itraconazole', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-nifedipine', 'itraconazole_cyp', 'Itraconazole', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-nisoldipine', 'itraconazole_cyp', 'Itraconazole', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-nimodipine', 'itraconazole_cyp', 'Itraconazole', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lercanidipine', 'itraconazole_cyp', 'Itraconazole', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-ivabradine_3a4', 'itraconazole_cyp', 'Itraconazole', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-ticagrelor_3a4', 'itraconazole_cyp', 'Itraconazole', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-rivaroxaban_3a4', 'itraconazole_cyp', 'Itraconazole', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-nilotinib_3a4', 'itraconazole_cyp', 'Itraconazole', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lapatinib_3a4', 'itraconazole_cyp', 'Itraconazole', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-palbociclib', 'itraconazole_cyp', 'Itraconazole', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-venetoclax', 'itraconazole_cyp', 'Itraconazole', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-olaparib', 'itraconazole_cyp', 'Itraconazole', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-ruxolitinib', 'itraconazole_cyp', 'Itraconazole', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-paclitaxel', 'itraconazole_cyp', 'Itraconazole', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-vincristine', 'itraconazole_cyp', 'Itraconazole', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-vinblastine', 'itraconazole_cyp', 'Itraconazole', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-maraviroc', 'itraconazole_cyp', 'Itraconazole', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lopinavir', 'itraconazole_cyp', 'Itraconazole', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-saquinavir', 'itraconazole_cyp', 'Itraconazole', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-quetiapine_3a4', 'itraconazole_cyp', 'Itraconazole', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lurasidone_3a4', 'itraconazole_cyp', 'Itraconazole', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-ziprasidone_3a4', 'itraconazole_cyp', 'Itraconazole', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-trazodone_3a4', 'itraconazole_cyp', 'Itraconazole', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-vilazodone', 'itraconazole_cyp', 'Itraconazole', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-tiagabine', 'itraconazole_cyp', 'Itraconazole', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-zonisamide', 'itraconazole_cyp', 'Itraconazole', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-zolpidem_3a4', 'itraconazole_cyp', 'Itraconazole', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-zaleplon', 'itraconazole_cyp', 'Itraconazole', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-suvorexant', 'itraconazole_cyp', 'Itraconazole', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-lemborexant', 'itraconazole_cyp', 'Itraconazole', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-methylprednisolone', 'itraconazole_cyp', 'Itraconazole', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-quinidine_3a4', 'itraconazole_cyp', 'Itraconazole', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-tamsulosin', 'itraconazole_cyp', 'Itraconazole', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-itraconazole_cyp-tolvaptan', 'itraconazole_cyp', 'Itraconazole', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-itraconazole_cyp', 'itraconazole_cyp', 'Itraconazole', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Itraconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Itraconazole and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Itraconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-simvastatin-voriconazole', 'voriconazole', 'Voriconazole', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-voriconazole', 'voriconazole', 'Voriconazole', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-voriconazole', 'voriconazole', 'Voriconazole', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-voriconazole', 'voriconazole', 'Voriconazole', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-triazolam-voriconazole', 'voriconazole', 'Voriconazole', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-voriconazole', 'voriconazole', 'Voriconazole', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-voriconazole', 'voriconazole', 'Voriconazole', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-voriconazole', 'voriconazole', 'Voriconazole', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tacrolimus-voriconazole', 'voriconazole', 'Voriconazole', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sirolimus-voriconazole', 'voriconazole', 'Voriconazole', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-voriconazole', 'voriconazole', 'Voriconazole', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-temsirolimus-voriconazole', 'voriconazole', 'Voriconazole', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-voriconazole', 'voriconazole', 'Voriconazole', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-voriconazole', 'voriconazole', 'Voriconazole', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-voriconazole', 'voriconazole', 'Voriconazole', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sufentanil-voriconazole', 'voriconazole', 'Voriconazole', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-voriconazole', 'voriconazole', 'Voriconazole', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sildenafil-voriconazole', 'voriconazole', 'Voriconazole', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tadalafil-voriconazole', 'voriconazole', 'Voriconazole', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-vardenafil-voriconazole', 'voriconazole', 'Voriconazole', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-voriconazole', 'voriconazole', 'Voriconazole', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-voriconazole', 'voriconazole', 'Voriconazole', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-voriconazole', 'voriconazole', 'Voriconazole', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-voriconazole', 'voriconazole', 'Voriconazole', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-voriconazole', 'voriconazole', 'Voriconazole', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-voriconazole', 'voriconazole', 'Voriconazole', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-voriconazole', 'voriconazole', 'Voriconazole', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-voriconazole', 'voriconazole', 'Voriconazole', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-voriconazole', 'voriconazole', 'Voriconazole', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-voriconazole', 'voriconazole', 'Voriconazole', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-voriconazole', 'voriconazole', 'Voriconazole', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-voriconazole', 'voriconazole', 'Voriconazole', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ticagrelor_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rivaroxaban_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-voriconazole', 'voriconazole', 'Voriconazole', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-voriconazole', 'voriconazole', 'Voriconazole', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-voriconazole', 'voriconazole', 'Voriconazole', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-voriconazole', 'voriconazole', 'Voriconazole', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-voriconazole', 'voriconazole', 'Voriconazole', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-voriconazole', 'voriconazole', 'Voriconazole', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-voriconazole', 'voriconazole', 'Voriconazole', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-voriconazole', 'voriconazole', 'Voriconazole', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-venetoclax-voriconazole', 'voriconazole', 'Voriconazole', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-voriconazole', 'voriconazole', 'Voriconazole', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ruxolitinib-voriconazole', 'voriconazole', 'Voriconazole', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-voriconazole', 'voriconazole', 'Voriconazole', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-voriconazole', 'voriconazole', 'Voriconazole', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-vincristine-voriconazole', 'voriconazole', 'Voriconazole', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-vinblastine-voriconazole', 'voriconazole', 'Voriconazole', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-voriconazole', 'voriconazole', 'Voriconazole', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-voriconazole', 'voriconazole', 'Voriconazole', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-voriconazole', 'voriconazole', 'Voriconazole', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-voriconazole', 'voriconazole', 'Voriconazole', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-voriconazole', 'voriconazole', 'Voriconazole', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-voriconazole', 'voriconazole', 'Voriconazole', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-saquinavir-voriconazole', 'voriconazole', 'Voriconazole', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-voriconazole-ziprasidone_3a4', 'voriconazole', 'Voriconazole', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-trazodone_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-vilazodone-voriconazole', 'voriconazole', 'Voriconazole', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tiagabine-voriconazole', 'voriconazole', 'Voriconazole', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-voriconazole-zonisamide', 'voriconazole', 'Voriconazole', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-voriconazole-zolpidem_3a4', 'voriconazole', 'Voriconazole', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-voriconazole-zaleplon', 'voriconazole', 'Voriconazole', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-suvorexant-voriconazole', 'voriconazole', 'Voriconazole', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-voriconazole', 'voriconazole', 'Voriconazole', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-voriconazole', 'voriconazole', 'Voriconazole', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-voriconazole', 'voriconazole', 'Voriconazole', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-voriconazole', 'voriconazole', 'Voriconazole', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-voriconazole', 'voriconazole', 'Voriconazole', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-voriconazole', 'voriconazole', 'Voriconazole', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-voriconazole', 'voriconazole', 'Voriconazole', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-voriconazole', 'voriconazole', 'Voriconazole', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-voriconazole', 'voriconazole', 'Voriconazole', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tamsulosin-voriconazole', 'voriconazole', 'Voriconazole', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-voriconazole', 'voriconazole', 'Voriconazole', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-voriconazole', 'voriconazole', 'Voriconazole', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tolvaptan-voriconazole', 'voriconazole', 'Voriconazole', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-voriconazole', 'voriconazole', 'Voriconazole', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Voriconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-simvastatin', 'posaconazole', 'Posaconazole', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-posaconazole', 'posaconazole', 'Posaconazole', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-posaconazole', 'posaconazole', 'Posaconazole', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-posaconazole', 'posaconazole', 'Posaconazole', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-triazolam', 'posaconazole', 'Posaconazole', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-posaconazole', 'posaconazole', 'Posaconazole', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-posaconazole', 'posaconazole', 'Posaconazole', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-posaconazole', 'posaconazole', 'Posaconazole', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-tacrolimus', 'posaconazole', 'Posaconazole', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-sirolimus', 'posaconazole', 'Posaconazole', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-posaconazole', 'posaconazole', 'Posaconazole', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-temsirolimus', 'posaconazole', 'Posaconazole', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-posaconazole', 'posaconazole', 'Posaconazole', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-posaconazole', 'posaconazole', 'Posaconazole', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-posaconazole', 'posaconazole', 'Posaconazole', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-sufentanil', 'posaconazole', 'Posaconazole', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-posaconazole', 'posaconazole', 'Posaconazole', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-sildenafil', 'posaconazole', 'Posaconazole', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-tadalafil', 'posaconazole', 'Posaconazole', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-vardenafil', 'posaconazole', 'Posaconazole', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-posaconazole', 'posaconazole', 'Posaconazole', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-posaconazole', 'posaconazole', 'Posaconazole', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-posaconazole', 'posaconazole', 'Posaconazole', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-posaconazole', 'posaconazole', 'Posaconazole', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-posaconazole', 'posaconazole', 'Posaconazole', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-posaconazole', 'posaconazole', 'Posaconazole', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-posaconazole', 'posaconazole', 'Posaconazole', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-posaconazole', 'posaconazole', 'Posaconazole', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-posaconazole', 'posaconazole', 'Posaconazole', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-posaconazole', 'posaconazole', 'Posaconazole', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-posaconazole', 'posaconazole', 'Posaconazole', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-posaconazole', 'posaconazole', 'Posaconazole', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-ticagrelor_3a4', 'posaconazole', 'Posaconazole', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-rivaroxaban_3a4', 'posaconazole', 'Posaconazole', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-posaconazole', 'posaconazole', 'Posaconazole', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-posaconazole', 'posaconazole', 'Posaconazole', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-posaconazole', 'posaconazole', 'Posaconazole', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-posaconazole', 'posaconazole', 'Posaconazole', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-posaconazole', 'posaconazole', 'Posaconazole', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-posaconazole', 'posaconazole', 'Posaconazole', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-posaconazole', 'posaconazole', 'Posaconazole', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-posaconazole', 'posaconazole', 'Posaconazole', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-venetoclax', 'posaconazole', 'Posaconazole', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-posaconazole', 'posaconazole', 'Posaconazole', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-ruxolitinib', 'posaconazole', 'Posaconazole', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-posaconazole', 'posaconazole', 'Posaconazole', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-posaconazole', 'posaconazole', 'Posaconazole', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-vincristine', 'posaconazole', 'Posaconazole', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-vinblastine', 'posaconazole', 'Posaconazole', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-posaconazole', 'posaconazole', 'Posaconazole', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-posaconazole', 'posaconazole', 'Posaconazole', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-posaconazole', 'posaconazole', 'Posaconazole', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-posaconazole', 'posaconazole', 'Posaconazole', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-posaconazole', 'posaconazole', 'Posaconazole', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-posaconazole', 'posaconazole', 'Posaconazole', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-saquinavir', 'posaconazole', 'Posaconazole', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-quetiapine_3a4', 'posaconazole', 'Posaconazole', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-ziprasidone_3a4', 'posaconazole', 'Posaconazole', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-trazodone_3a4', 'posaconazole', 'Posaconazole', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-vilazodone', 'posaconazole', 'Posaconazole', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-tiagabine', 'posaconazole', 'Posaconazole', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-zonisamide', 'posaconazole', 'Posaconazole', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-zolpidem_3a4', 'posaconazole', 'Posaconazole', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-zaleplon', 'posaconazole', 'Posaconazole', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-posaconazole', 'posaconazole', 'Posaconazole', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-suvorexant', 'posaconazole', 'Posaconazole', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-posaconazole', 'posaconazole', 'Posaconazole', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-posaconazole', 'posaconazole', 'Posaconazole', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-posaconazole', 'posaconazole', 'Posaconazole', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-posaconazole', 'posaconazole', 'Posaconazole', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-posaconazole', 'posaconazole', 'Posaconazole', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-posaconazole', 'posaconazole', 'Posaconazole', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-quinidine_3a4', 'posaconazole', 'Posaconazole', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-posaconazole', 'posaconazole', 'Posaconazole', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-posaconazole', 'posaconazole', 'Posaconazole', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-tamsulosin', 'posaconazole', 'Posaconazole', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-posaconazole', 'posaconazole', 'Posaconazole', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-posaconazole', 'posaconazole', 'Posaconazole', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-posaconazole-tolvaptan', 'posaconazole', 'Posaconazole', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-posaconazole', 'posaconazole', 'Posaconazole', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Posaconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Posaconazole and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Posaconazole is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-simvastatin', 'ritonavir', 'Ritonavir', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-ritonavir', 'ritonavir', 'Ritonavir', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-ritonavir', 'ritonavir', 'Ritonavir', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-ritonavir', 'ritonavir', 'Ritonavir', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-triazolam', 'ritonavir', 'Ritonavir', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-ritonavir', 'ritonavir', 'Ritonavir', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-ritonavir', 'ritonavir', 'Ritonavir', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-ritonavir', 'ritonavir', 'Ritonavir', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-tacrolimus', 'ritonavir', 'Ritonavir', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-sirolimus', 'ritonavir', 'Ritonavir', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-ritonavir', 'ritonavir', 'Ritonavir', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-temsirolimus', 'ritonavir', 'Ritonavir', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-ritonavir', 'ritonavir', 'Ritonavir', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-ritonavir', 'ritonavir', 'Ritonavir', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-ritonavir', 'ritonavir', 'Ritonavir', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-sufentanil', 'ritonavir', 'Ritonavir', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-ritonavir', 'ritonavir', 'Ritonavir', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-sildenafil', 'ritonavir', 'Ritonavir', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-tadalafil', 'ritonavir', 'Ritonavir', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-vardenafil', 'ritonavir', 'Ritonavir', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-ritonavir', 'ritonavir', 'Ritonavir', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-ritonavir', 'ritonavir', 'Ritonavir', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-ritonavir', 'ritonavir', 'Ritonavir', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-ritonavir', 'ritonavir', 'Ritonavir', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-ritonavir', 'ritonavir', 'Ritonavir', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-ritonavir', 'ritonavir', 'Ritonavir', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-ritonavir', 'ritonavir', 'Ritonavir', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-ritonavir', 'ritonavir', 'Ritonavir', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-ritonavir', 'ritonavir', 'Ritonavir', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-ritonavir', 'ritonavir', 'Ritonavir', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-ritonavir', 'ritonavir', 'Ritonavir', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-ritonavir', 'ritonavir', 'Ritonavir', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-ticagrelor_3a4', 'ritonavir', 'Ritonavir', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-rivaroxaban_3a4', 'ritonavir', 'Ritonavir', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-ritonavir', 'ritonavir', 'Ritonavir', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-ritonavir', 'ritonavir', 'Ritonavir', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-ritonavir', 'ritonavir', 'Ritonavir', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-ritonavir', 'ritonavir', 'Ritonavir', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-ritonavir', 'ritonavir', 'Ritonavir', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-ritonavir', 'ritonavir', 'Ritonavir', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-ritonavir', 'ritonavir', 'Ritonavir', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-ritonavir', 'ritonavir', 'Ritonavir', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-venetoclax', 'ritonavir', 'Ritonavir', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-ritonavir', 'ritonavir', 'Ritonavir', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-ruxolitinib', 'ritonavir', 'Ritonavir', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-ritonavir', 'ritonavir', 'Ritonavir', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-ritonavir', 'ritonavir', 'Ritonavir', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-vincristine', 'ritonavir', 'Ritonavir', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-vinblastine', 'ritonavir', 'Ritonavir', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-ritonavir', 'ritonavir', 'Ritonavir', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-ritonavir', 'ritonavir', 'Ritonavir', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-ritonavir', 'ritonavir', 'Ritonavir', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-ritonavir', 'ritonavir', 'Ritonavir', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-ritonavir', 'ritonavir', 'Ritonavir', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-ritonavir', 'ritonavir', 'Ritonavir', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-saquinavir', 'ritonavir', 'Ritonavir', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-ziprasidone_3a4', 'ritonavir', 'Ritonavir', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-trazodone_3a4', 'ritonavir', 'Ritonavir', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-vilazodone', 'ritonavir', 'Ritonavir', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-tiagabine', 'ritonavir', 'Ritonavir', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-zonisamide', 'ritonavir', 'Ritonavir', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-zolpidem_3a4', 'ritonavir', 'Ritonavir', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-zaleplon', 'ritonavir', 'Ritonavir', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-suvorexant', 'ritonavir', 'Ritonavir', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-ritonavir', 'ritonavir', 'Ritonavir', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-ritonavir', 'ritonavir', 'Ritonavir', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-ritonavir', 'ritonavir', 'Ritonavir', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-ritonavir', 'ritonavir', 'Ritonavir', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-ritonavir', 'ritonavir', 'Ritonavir', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-ritonavir', 'ritonavir', 'Ritonavir', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-ritonavir', 'ritonavir', 'Ritonavir', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-ritonavir', 'ritonavir', 'Ritonavir', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-ritonavir', 'ritonavir', 'Ritonavir', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-tamsulosin', 'ritonavir', 'Ritonavir', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-ritonavir', 'ritonavir', 'Ritonavir', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-ritonavir', 'ritonavir', 'Ritonavir', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ritonavir-tolvaptan', 'ritonavir', 'Ritonavir', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-ritonavir', 'ritonavir', 'Ritonavir', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Ritonavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ritonavir and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ritonavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-simvastatin', 'cobicistat', 'Cobicistat', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lovastatin', 'cobicistat', 'Cobicistat', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-cobicistat', 'cobicistat', 'Cobicistat', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-midazolam', 'cobicistat', 'Cobicistat', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-triazolam', 'cobicistat', 'Cobicistat', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-cobicistat', 'cobicistat', 'Cobicistat', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-diazepam_3a4', 'cobicistat', 'Cobicistat', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-cobicistat', 'cobicistat', 'Cobicistat', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-cyclosporine', 'cobicistat', 'Cobicistat', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-tacrolimus', 'cobicistat', 'Cobicistat', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-sirolimus', 'cobicistat', 'Cobicistat', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-everolimus', 'cobicistat', 'Cobicistat', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-temsirolimus', 'cobicistat', 'Cobicistat', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-fentanyl', 'cobicistat', 'Cobicistat', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-oxycodone', 'cobicistat', 'Cobicistat', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-cobicistat', 'cobicistat', 'Cobicistat', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-sufentanil', 'cobicistat', 'Cobicistat', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-methadone_3a4', 'cobicistat', 'Cobicistat', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-cobicistat', 'cobicistat', 'Cobicistat', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-sildenafil', 'cobicistat', 'Cobicistat', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-tadalafil', 'cobicistat', 'Cobicistat', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-vardenafil', 'cobicistat', 'Cobicistat', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-cobicistat', 'cobicistat', 'Cobicistat', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-cobicistat', 'cobicistat', 'Cobicistat', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-felodipine', 'cobicistat', 'Cobicistat', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-nifedipine', 'cobicistat', 'Cobicistat', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-nisoldipine', 'cobicistat', 'Cobicistat', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-nimodipine', 'cobicistat', 'Cobicistat', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-isradipine', 'cobicistat', 'Cobicistat', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lercanidipine', 'cobicistat', 'Cobicistat', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-colchicine', 'cobicistat', 'Cobicistat', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ergotamine', 'cobicistat', 'Cobicistat', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-cobicistat', 'cobicistat', 'Cobicistat', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-eplerenone', 'cobicistat', 'Cobicistat', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ivabradine_3a4', 'cobicistat', 'Cobicistat', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-dronedarone_3a4', 'cobicistat', 'Cobicistat', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ticagrelor_3a4', 'cobicistat', 'Cobicistat', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-cobicistat', 'cobicistat', 'Cobicistat', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-rivaroxaban_3a4', 'cobicistat', 'Cobicistat', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-imatinib', 'cobicistat', 'Cobicistat', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-dasatinib', 'cobicistat', 'Cobicistat', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-nilotinib_3a4', 'cobicistat', 'Cobicistat', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-erlotinib', 'cobicistat', 'Cobicistat', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-gefitinib', 'cobicistat', 'Cobicistat', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lapatinib_3a4', 'cobicistat', 'Cobicistat', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-cobicistat', 'cobicistat', 'Cobicistat', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-cobicistat', 'cobicistat', 'Cobicistat', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ibrutinib', 'cobicistat', 'Cobicistat', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-palbociclib', 'cobicistat', 'Cobicistat', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-venetoclax', 'cobicistat', 'Cobicistat', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-olaparib', 'cobicistat', 'Cobicistat', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ruxolitinib', 'cobicistat', 'Cobicistat', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-docetaxel', 'cobicistat', 'Cobicistat', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-paclitaxel', 'cobicistat', 'Cobicistat', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-vincristine', 'cobicistat', 'Cobicistat', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-vinblastine', 'cobicistat', 'Cobicistat', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-etoposide', 'cobicistat', 'Cobicistat', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-irinotecan', 'cobicistat', 'Cobicistat', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-maraviroc', 'cobicistat', 'Cobicistat', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-cobicistat', 'cobicistat', 'Cobicistat', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-darunavir', 'cobicistat', 'Cobicistat', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lopinavir', 'cobicistat', 'Cobicistat', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-saquinavir', 'cobicistat', 'Cobicistat', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-quetiapine_3a4', 'cobicistat', 'Cobicistat', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lurasidone_3a4', 'cobicistat', 'Cobicistat', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-cobicistat', 'cobicistat', 'Cobicistat', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-ziprasidone_3a4', 'cobicistat', 'Cobicistat', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-trazodone_3a4', 'cobicistat', 'Cobicistat', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-vilazodone', 'cobicistat', 'Cobicistat', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-cobicistat', 'cobicistat', 'Cobicistat', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-tiagabine', 'cobicistat', 'Cobicistat', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-zonisamide', 'cobicistat', 'Cobicistat', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-zolpidem_3a4', 'cobicistat', 'Cobicistat', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-zaleplon', 'cobicistat', 'Cobicistat', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-eszopiclone_3a4', 'cobicistat', 'Cobicistat', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-suvorexant', 'cobicistat', 'Cobicistat', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-lemborexant', 'cobicistat', 'Cobicistat', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-hydrocortisone', 'cobicistat', 'Cobicistat', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-cobicistat', 'cobicistat', 'Cobicistat', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-methylprednisolone', 'cobicistat', 'Cobicistat', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-dexamethasone', 'cobicistat', 'Cobicistat', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-fluticasone', 'cobicistat', 'Cobicistat', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-quinidine_3a4', 'cobicistat', 'Cobicistat', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-eletriptan', 'cobicistat', 'Cobicistat', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-cobicistat', 'cobicistat', 'Cobicistat', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-tamsulosin', 'cobicistat', 'Cobicistat', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-finasteride', 'cobicistat', 'Cobicistat', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-dutasteride', 'cobicistat', 'Cobicistat', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-tolvaptan', 'cobicistat', 'Cobicistat', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cobicistat-conivaptan', 'cobicistat', 'Cobicistat', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Cobicistat is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cobicistat and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cobicistat is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-simvastatin', 'nelfinavir', 'Nelfinavir', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-nelfinavir', 'nelfinavir', 'Nelfinavir', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-nelfinavir', 'nelfinavir', 'Nelfinavir', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-triazolam', 'nelfinavir', 'Nelfinavir', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-nelfinavir', 'nelfinavir', 'Nelfinavir', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-nelfinavir', 'nelfinavir', 'Nelfinavir', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-tacrolimus', 'nelfinavir', 'Nelfinavir', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-sirolimus', 'nelfinavir', 'Nelfinavir', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-nelfinavir', 'nelfinavir', 'Nelfinavir', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-temsirolimus', 'nelfinavir', 'Nelfinavir', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-nelfinavir', 'nelfinavir', 'Nelfinavir', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-oxycodone', 'nelfinavir', 'Nelfinavir', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-nelfinavir', 'nelfinavir', 'Nelfinavir', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-sufentanil', 'nelfinavir', 'Nelfinavir', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-sildenafil', 'nelfinavir', 'Nelfinavir', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-tadalafil', 'nelfinavir', 'Nelfinavir', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-vardenafil', 'nelfinavir', 'Nelfinavir', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-nelfinavir', 'nelfinavir', 'Nelfinavir', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-nifedipine', 'nelfinavir', 'Nelfinavir', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-nisoldipine', 'nelfinavir', 'Nelfinavir', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-nimodipine', 'nelfinavir', 'Nelfinavir', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-nelfinavir', 'nelfinavir', 'Nelfinavir', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-ticagrelor_3a4', 'nelfinavir', 'Nelfinavir', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-rivaroxaban_3a4', 'nelfinavir', 'Nelfinavir', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-nilotinib_3a4', 'nelfinavir', 'Nelfinavir', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-nelfinavir', 'nelfinavir', 'Nelfinavir', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-palbociclib', 'nelfinavir', 'Nelfinavir', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-venetoclax', 'nelfinavir', 'Nelfinavir', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-olaparib', 'nelfinavir', 'Nelfinavir', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-ruxolitinib', 'nelfinavir', 'Nelfinavir', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-nelfinavir', 'nelfinavir', 'Nelfinavir', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-paclitaxel', 'nelfinavir', 'Nelfinavir', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-vincristine', 'nelfinavir', 'Nelfinavir', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-vinblastine', 'nelfinavir', 'Nelfinavir', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-nelfinavir', 'nelfinavir', 'Nelfinavir', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-nelfinavir', 'nelfinavir', 'Nelfinavir', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-nelfinavir', 'nelfinavir', 'Nelfinavir', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-nelfinavir', 'nelfinavir', 'Nelfinavir', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-nelfinavir', 'nelfinavir', 'Nelfinavir', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-saquinavir', 'nelfinavir', 'Nelfinavir', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-quetiapine_3a4', 'nelfinavir', 'Nelfinavir', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-ziprasidone_3a4', 'nelfinavir', 'Nelfinavir', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-trazodone_3a4', 'nelfinavir', 'Nelfinavir', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-vilazodone', 'nelfinavir', 'Nelfinavir', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-tiagabine', 'nelfinavir', 'Nelfinavir', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-zonisamide', 'nelfinavir', 'Nelfinavir', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-zolpidem_3a4', 'nelfinavir', 'Nelfinavir', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-zaleplon', 'nelfinavir', 'Nelfinavir', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-nelfinavir', 'nelfinavir', 'Nelfinavir', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-suvorexant', 'nelfinavir', 'Nelfinavir', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-nelfinavir', 'nelfinavir', 'Nelfinavir', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-nelfinavir', 'nelfinavir', 'Nelfinavir', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-nelfinavir', 'nelfinavir', 'Nelfinavir', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-quinidine_3a4', 'nelfinavir', 'Nelfinavir', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-nelfinavir', 'nelfinavir', 'Nelfinavir', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-nelfinavir', 'nelfinavir', 'Nelfinavir', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-tamsulosin', 'nelfinavir', 'Nelfinavir', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-nelfinavir', 'nelfinavir', 'Nelfinavir', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-nelfinavir', 'nelfinavir', 'Nelfinavir', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nelfinavir-tolvaptan', 'nelfinavir', 'Nelfinavir', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-nelfinavir', 'nelfinavir', 'Nelfinavir', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nelfinavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nelfinavir and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nelfinavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-simvastatin', 'indinavir', 'Indinavir', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lovastatin', 'indinavir', 'Indinavir', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-indinavir', 'indinavir', 'Indinavir', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-midazolam', 'indinavir', 'Indinavir', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-triazolam', 'indinavir', 'Indinavir', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-indinavir', 'indinavir', 'Indinavir', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-indinavir', 'indinavir', 'Indinavir', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-indinavir', 'indinavir', 'Indinavir', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-indinavir', 'indinavir', 'Indinavir', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-tacrolimus', 'indinavir', 'Indinavir', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-sirolimus', 'indinavir', 'Indinavir', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-indinavir', 'indinavir', 'Indinavir', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-temsirolimus', 'indinavir', 'Indinavir', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-indinavir', 'indinavir', 'Indinavir', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-oxycodone', 'indinavir', 'Indinavir', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-indinavir', 'indinavir', 'Indinavir', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-sufentanil', 'indinavir', 'Indinavir', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-methadone_3a4', 'indinavir', 'Indinavir', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-indinavir', 'indinavir', 'Indinavir', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-sildenafil', 'indinavir', 'Indinavir', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-tadalafil', 'indinavir', 'Indinavir', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-vardenafil', 'indinavir', 'Indinavir', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-indinavir', 'indinavir', 'Indinavir', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-indinavir', 'indinavir', 'Indinavir', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-indinavir', 'indinavir', 'Indinavir', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-nifedipine', 'indinavir', 'Indinavir', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-nisoldipine', 'indinavir', 'Indinavir', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-nimodipine', 'indinavir', 'Indinavir', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-isradipine', 'indinavir', 'Indinavir', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lercanidipine', 'indinavir', 'Indinavir', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-indinavir', 'indinavir', 'Indinavir', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-indinavir', 'indinavir', 'Indinavir', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-indinavir', 'indinavir', 'Indinavir', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-indinavir', 'indinavir', 'Indinavir', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-ivabradine_3a4', 'indinavir', 'Indinavir', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-indinavir', 'indinavir', 'Indinavir', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-ticagrelor_3a4', 'indinavir', 'Indinavir', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-indinavir', 'indinavir', 'Indinavir', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-rivaroxaban_3a4', 'indinavir', 'Indinavir', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-indinavir', 'indinavir', 'Indinavir', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-indinavir', 'indinavir', 'Indinavir', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-nilotinib_3a4', 'indinavir', 'Indinavir', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-indinavir', 'indinavir', 'Indinavir', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-indinavir', 'indinavir', 'Indinavir', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lapatinib_3a4', 'indinavir', 'Indinavir', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-indinavir', 'indinavir', 'Indinavir', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-indinavir', 'indinavir', 'Indinavir', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-indinavir', 'indinavir', 'Indinavir', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-palbociclib', 'indinavir', 'Indinavir', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-venetoclax', 'indinavir', 'Indinavir', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-olaparib', 'indinavir', 'Indinavir', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-ruxolitinib', 'indinavir', 'Indinavir', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-indinavir', 'indinavir', 'Indinavir', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-paclitaxel', 'indinavir', 'Indinavir', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-vincristine', 'indinavir', 'Indinavir', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-vinblastine', 'indinavir', 'Indinavir', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-indinavir', 'indinavir', 'Indinavir', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-irinotecan', 'indinavir', 'Indinavir', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-maraviroc', 'indinavir', 'Indinavir', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-indinavir', 'indinavir', 'Indinavir', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-indinavir', 'indinavir', 'Indinavir', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lopinavir', 'indinavir', 'Indinavir', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-saquinavir', 'indinavir', 'Indinavir', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-quetiapine_3a4', 'indinavir', 'Indinavir', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lurasidone_3a4', 'indinavir', 'Indinavir', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-indinavir', 'indinavir', 'Indinavir', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-ziprasidone_3a4', 'indinavir', 'Indinavir', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-trazodone_3a4', 'indinavir', 'Indinavir', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-vilazodone', 'indinavir', 'Indinavir', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-indinavir', 'indinavir', 'Indinavir', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-tiagabine', 'indinavir', 'Indinavir', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-zonisamide', 'indinavir', 'Indinavir', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-zolpidem_3a4', 'indinavir', 'Indinavir', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-zaleplon', 'indinavir', 'Indinavir', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-indinavir', 'indinavir', 'Indinavir', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-suvorexant', 'indinavir', 'Indinavir', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-lemborexant', 'indinavir', 'Indinavir', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-indinavir', 'indinavir', 'Indinavir', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-indinavir', 'indinavir', 'Indinavir', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-methylprednisolone', 'indinavir', 'Indinavir', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-indinavir', 'indinavir', 'Indinavir', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-indinavir', 'indinavir', 'Indinavir', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-quinidine_3a4', 'indinavir', 'Indinavir', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-indinavir', 'indinavir', 'Indinavir', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-indinavir', 'indinavir', 'Indinavir', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-tamsulosin', 'indinavir', 'Indinavir', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-indinavir', 'indinavir', 'Indinavir', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-indinavir', 'indinavir', 'Indinavir', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-indinavir-tolvaptan', 'indinavir', 'Indinavir', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-indinavir', 'indinavir', 'Indinavir', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Indinavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Indinavir and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Indinavir is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-simvastatin', 'clarithromycin_cyp', 'Clarithromycin', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lovastatin', 'clarithromycin_cyp', 'Clarithromycin', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-midazolam', 'clarithromycin_cyp', 'Clarithromycin', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-triazolam', 'clarithromycin_cyp', 'Clarithromycin', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-diazepam_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-clorazepate', 'clarithromycin_cyp', 'Clarithromycin', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-cyclosporine', 'clarithromycin_cyp', 'Clarithromycin', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-tacrolimus', 'clarithromycin_cyp', 'Clarithromycin', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-sirolimus', 'clarithromycin_cyp', 'Clarithromycin', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-everolimus', 'clarithromycin_cyp', 'Clarithromycin', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-temsirolimus', 'clarithromycin_cyp', 'Clarithromycin', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-fentanyl', 'clarithromycin_cyp', 'Clarithromycin', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-oxycodone', 'clarithromycin_cyp', 'Clarithromycin', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-sufentanil', 'clarithromycin_cyp', 'Clarithromycin', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-methadone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-sildenafil', 'clarithromycin_cyp', 'Clarithromycin', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-tadalafil', 'clarithromycin_cyp', 'Clarithromycin', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-vardenafil', 'clarithromycin_cyp', 'Clarithromycin', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-felodipine', 'clarithromycin_cyp', 'Clarithromycin', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-nifedipine', 'clarithromycin_cyp', 'Clarithromycin', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-nisoldipine', 'clarithromycin_cyp', 'Clarithromycin', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-nimodipine', 'clarithromycin_cyp', 'Clarithromycin', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-isradipine', 'clarithromycin_cyp', 'Clarithromycin', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lercanidipine', 'clarithromycin_cyp', 'Clarithromycin', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-colchicine', 'clarithromycin_cyp', 'Clarithromycin', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ergotamine', 'clarithromycin_cyp', 'Clarithromycin', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-eplerenone', 'clarithromycin_cyp', 'Clarithromycin', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ivabradine_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-dronedarone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ticagrelor_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-rivaroxaban_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-imatinib', 'clarithromycin_cyp', 'Clarithromycin', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-dasatinib', 'clarithromycin_cyp', 'Clarithromycin', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-nilotinib_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-erlotinib', 'clarithromycin_cyp', 'Clarithromycin', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-gefitinib', 'clarithromycin_cyp', 'Clarithromycin', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lapatinib_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ibrutinib', 'clarithromycin_cyp', 'Clarithromycin', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-palbociclib', 'clarithromycin_cyp', 'Clarithromycin', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-venetoclax', 'clarithromycin_cyp', 'Clarithromycin', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-olaparib', 'clarithromycin_cyp', 'Clarithromycin', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ruxolitinib', 'clarithromycin_cyp', 'Clarithromycin', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-docetaxel', 'clarithromycin_cyp', 'Clarithromycin', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-paclitaxel', 'clarithromycin_cyp', 'Clarithromycin', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-vincristine', 'clarithromycin_cyp', 'Clarithromycin', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-vinblastine', 'clarithromycin_cyp', 'Clarithromycin', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-etoposide', 'clarithromycin_cyp', 'Clarithromycin', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-irinotecan', 'clarithromycin_cyp', 'Clarithromycin', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-maraviroc', 'clarithromycin_cyp', 'Clarithromycin', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-darunavir', 'clarithromycin_cyp', 'Clarithromycin', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lopinavir', 'clarithromycin_cyp', 'Clarithromycin', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-saquinavir', 'clarithromycin_cyp', 'Clarithromycin', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-quetiapine_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lurasidone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-ziprasidone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-trazodone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-vilazodone', 'clarithromycin_cyp', 'Clarithromycin', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-tiagabine', 'clarithromycin_cyp', 'Clarithromycin', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-zonisamide', 'clarithromycin_cyp', 'Clarithromycin', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-zolpidem_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-zaleplon', 'clarithromycin_cyp', 'Clarithromycin', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-eszopiclone_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-suvorexant', 'clarithromycin_cyp', 'Clarithromycin', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-lemborexant', 'clarithromycin_cyp', 'Clarithromycin', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-hydrocortisone', 'clarithromycin_cyp', 'Clarithromycin', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-methylprednisolone', 'clarithromycin_cyp', 'Clarithromycin', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-dexamethasone', 'clarithromycin_cyp', 'Clarithromycin', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-fluticasone', 'clarithromycin_cyp', 'Clarithromycin', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-quinidine_3a4', 'clarithromycin_cyp', 'Clarithromycin', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-eletriptan', 'clarithromycin_cyp', 'Clarithromycin', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-clarithromycin_cyp', 'clarithromycin_cyp', 'Clarithromycin', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-tamsulosin', 'clarithromycin_cyp', 'Clarithromycin', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-finasteride', 'clarithromycin_cyp', 'Clarithromycin', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-dutasteride', 'clarithromycin_cyp', 'Clarithromycin', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-tolvaptan', 'clarithromycin_cyp', 'Clarithromycin', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clarithromycin_cyp-conivaptan', 'clarithromycin_cyp', 'Clarithromycin', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Clarithromycin is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Clarithromycin and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Clarithromycin is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-simvastatin-telithromycin', 'telithromycin', 'Telithromycin', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-telithromycin', 'telithromycin', 'Telithromycin', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-telithromycin', 'telithromycin', 'Telithromycin', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-telithromycin', 'telithromycin', 'Telithromycin', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-triazolam', 'telithromycin', 'Telithromycin', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-telithromycin', 'telithromycin', 'Telithromycin', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-telithromycin', 'telithromycin', 'Telithromycin', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-telithromycin', 'telithromycin', 'Telithromycin', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tacrolimus-telithromycin', 'telithromycin', 'Telithromycin', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sirolimus-telithromycin', 'telithromycin', 'Telithromycin', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-telithromycin', 'telithromycin', 'Telithromycin', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-temsirolimus', 'telithromycin', 'Telithromycin', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-telithromycin', 'telithromycin', 'Telithromycin', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-telithromycin', 'telithromycin', 'Telithromycin', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-telithromycin', 'telithromycin', 'Telithromycin', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sufentanil-telithromycin', 'telithromycin', 'Telithromycin', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-telithromycin', 'telithromycin', 'Telithromycin', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sildenafil-telithromycin', 'telithromycin', 'Telithromycin', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tadalafil-telithromycin', 'telithromycin', 'Telithromycin', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-vardenafil', 'telithromycin', 'Telithromycin', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-telithromycin', 'telithromycin', 'Telithromycin', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-telithromycin', 'telithromycin', 'Telithromycin', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-telithromycin', 'telithromycin', 'Telithromycin', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-telithromycin', 'telithromycin', 'Telithromycin', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-telithromycin', 'telithromycin', 'Telithromycin', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-telithromycin', 'telithromycin', 'Telithromycin', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-telithromycin', 'telithromycin', 'Telithromycin', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-telithromycin', 'telithromycin', 'Telithromycin', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-telithromycin', 'telithromycin', 'Telithromycin', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-telithromycin', 'telithromycin', 'Telithromycin', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-telithromycin', 'telithromycin', 'Telithromycin', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-telithromycin', 'telithromycin', 'Telithromycin', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-ticagrelor_3a4', 'telithromycin', 'Telithromycin', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rivaroxaban_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-telithromycin', 'telithromycin', 'Telithromycin', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-telithromycin', 'telithromycin', 'Telithromycin', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-telithromycin', 'telithromycin', 'Telithromycin', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-telithromycin', 'telithromycin', 'Telithromycin', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-telithromycin', 'telithromycin', 'Telithromycin', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-telithromycin', 'telithromycin', 'Telithromycin', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-telithromycin', 'telithromycin', 'Telithromycin', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-telithromycin', 'telithromycin', 'Telithromycin', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-venetoclax', 'telithromycin', 'Telithromycin', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-telithromycin', 'telithromycin', 'Telithromycin', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ruxolitinib-telithromycin', 'telithromycin', 'Telithromycin', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-telithromycin', 'telithromycin', 'Telithromycin', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-telithromycin', 'telithromycin', 'Telithromycin', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-vincristine', 'telithromycin', 'Telithromycin', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-vinblastine', 'telithromycin', 'Telithromycin', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-telithromycin', 'telithromycin', 'Telithromycin', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-telithromycin', 'telithromycin', 'Telithromycin', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-telithromycin', 'telithromycin', 'Telithromycin', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-telithromycin', 'telithromycin', 'Telithromycin', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-telithromycin', 'telithromycin', 'Telithromycin', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-telithromycin', 'telithromycin', 'Telithromycin', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-saquinavir-telithromycin', 'telithromycin', 'Telithromycin', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-ziprasidone_3a4', 'telithromycin', 'Telithromycin', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-trazodone_3a4', 'telithromycin', 'Telithromycin', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-vilazodone', 'telithromycin', 'Telithromycin', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-tiagabine', 'telithromycin', 'Telithromycin', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-zonisamide', 'telithromycin', 'Telithromycin', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-zolpidem_3a4', 'telithromycin', 'Telithromycin', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-zaleplon', 'telithromycin', 'Telithromycin', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-suvorexant-telithromycin', 'telithromycin', 'Telithromycin', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-telithromycin', 'telithromycin', 'Telithromycin', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-telithromycin', 'telithromycin', 'Telithromycin', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-telithromycin', 'telithromycin', 'Telithromycin', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-telithromycin', 'telithromycin', 'Telithromycin', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-telithromycin', 'telithromycin', 'Telithromycin', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-telithromycin', 'telithromycin', 'Telithromycin', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-telithromycin', 'telithromycin', 'Telithromycin', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-telithromycin', 'telithromycin', 'Telithromycin', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-telithromycin', 'telithromycin', 'Telithromycin', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tamsulosin-telithromycin', 'telithromycin', 'Telithromycin', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-telithromycin', 'telithromycin', 'Telithromycin', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-telithromycin', 'telithromycin', 'Telithromycin', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-telithromycin-tolvaptan', 'telithromycin', 'Telithromycin', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-telithromycin', 'telithromycin', 'Telithromycin', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Telithromycin is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Telithromycin and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Telithromycin is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-simvastatin', 'nefazodone', 'Nefazodone', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-nefazodone', 'nefazodone', 'Nefazodone', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-nefazodone', 'nefazodone', 'Nefazodone', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-nefazodone', 'nefazodone', 'Nefazodone', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-triazolam', 'nefazodone', 'Nefazodone', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-nefazodone', 'nefazodone', 'Nefazodone', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-nefazodone', 'nefazodone', 'Nefazodone', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-nefazodone', 'nefazodone', 'Nefazodone', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-tacrolimus', 'nefazodone', 'Nefazodone', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-sirolimus', 'nefazodone', 'Nefazodone', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-nefazodone', 'nefazodone', 'Nefazodone', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-temsirolimus', 'nefazodone', 'Nefazodone', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-nefazodone', 'nefazodone', 'Nefazodone', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-oxycodone', 'nefazodone', 'Nefazodone', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-nefazodone', 'nefazodone', 'Nefazodone', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-sufentanil', 'nefazodone', 'Nefazodone', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-nefazodone', 'nefazodone', 'Nefazodone', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-sildenafil', 'nefazodone', 'Nefazodone', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-tadalafil', 'nefazodone', 'Nefazodone', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-vardenafil', 'nefazodone', 'Nefazodone', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-nefazodone', 'nefazodone', 'Nefazodone', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-nefazodone', 'nefazodone', 'Nefazodone', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-nefazodone', 'nefazodone', 'Nefazodone', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-nifedipine', 'nefazodone', 'Nefazodone', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-nisoldipine', 'nefazodone', 'Nefazodone', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-nimodipine', 'nefazodone', 'Nefazodone', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-nefazodone', 'nefazodone', 'Nefazodone', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-nefazodone', 'nefazodone', 'Nefazodone', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-nefazodone', 'nefazodone', 'Nefazodone', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-nefazodone', 'nefazodone', 'Nefazodone', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-nefazodone', 'nefazodone', 'Nefazodone', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-nefazodone', 'nefazodone', 'Nefazodone', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-ticagrelor_3a4', 'nefazodone', 'Nefazodone', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-rivaroxaban_3a4', 'nefazodone', 'Nefazodone', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-nefazodone', 'nefazodone', 'Nefazodone', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-nefazodone', 'nefazodone', 'Nefazodone', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-nilotinib_3a4', 'nefazodone', 'Nefazodone', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-nefazodone', 'nefazodone', 'Nefazodone', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-nefazodone', 'nefazodone', 'Nefazodone', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-nefazodone', 'nefazodone', 'Nefazodone', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-nefazodone', 'nefazodone', 'Nefazodone', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-nefazodone', 'nefazodone', 'Nefazodone', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-palbociclib', 'nefazodone', 'Nefazodone', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-venetoclax', 'nefazodone', 'Nefazodone', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-olaparib', 'nefazodone', 'Nefazodone', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-ruxolitinib', 'nefazodone', 'Nefazodone', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-nefazodone', 'nefazodone', 'Nefazodone', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-paclitaxel', 'nefazodone', 'Nefazodone', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-vincristine', 'nefazodone', 'Nefazodone', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-vinblastine', 'nefazodone', 'Nefazodone', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-nefazodone', 'nefazodone', 'Nefazodone', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-nefazodone', 'nefazodone', 'Nefazodone', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-nefazodone', 'nefazodone', 'Nefazodone', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-nefazodone', 'nefazodone', 'Nefazodone', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-nefazodone', 'nefazodone', 'Nefazodone', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-nefazodone', 'nefazodone', 'Nefazodone', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-saquinavir', 'nefazodone', 'Nefazodone', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-quetiapine_3a4', 'nefazodone', 'Nefazodone', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-ziprasidone_3a4', 'nefazodone', 'Nefazodone', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-trazodone_3a4', 'nefazodone', 'Nefazodone', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-vilazodone', 'nefazodone', 'Nefazodone', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-tiagabine', 'nefazodone', 'Nefazodone', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-zonisamide', 'nefazodone', 'Nefazodone', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-zolpidem_3a4', 'nefazodone', 'Nefazodone', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-zaleplon', 'nefazodone', 'Nefazodone', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-nefazodone', 'nefazodone', 'Nefazodone', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-suvorexant', 'nefazodone', 'Nefazodone', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-nefazodone', 'nefazodone', 'Nefazodone', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-nefazodone', 'nefazodone', 'Nefazodone', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-nefazodone', 'nefazodone', 'Nefazodone', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-nefazodone', 'nefazodone', 'Nefazodone', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-nefazodone', 'nefazodone', 'Nefazodone', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-nefazodone', 'nefazodone', 'Nefazodone', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-quinidine_3a4', 'nefazodone', 'Nefazodone', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-nefazodone', 'nefazodone', 'Nefazodone', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-nefazodone', 'nefazodone', 'Nefazodone', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-tamsulosin', 'nefazodone', 'Nefazodone', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-nefazodone', 'nefazodone', 'Nefazodone', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-nefazodone', 'nefazodone', 'Nefazodone', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nefazodone-tolvaptan', 'nefazodone', 'Nefazodone', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-nefazodone', 'nefazodone', 'Nefazodone', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Nefazodone is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Nefazodone and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Nefazodone is a strong CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-simvastatin', 'diltiazem', 'Diltiazem', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lovastatin', 'diltiazem', 'Diltiazem', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-diltiazem', 'diltiazem', 'Diltiazem', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-midazolam', 'diltiazem', 'Diltiazem', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-triazolam', 'diltiazem', 'Diltiazem', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-diltiazem', 'diltiazem', 'Diltiazem', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-diltiazem', 'diltiazem', 'Diltiazem', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-diltiazem', 'diltiazem', 'Diltiazem', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-diltiazem', 'diltiazem', 'Diltiazem', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-tacrolimus', 'diltiazem', 'Diltiazem', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-sirolimus', 'diltiazem', 'Diltiazem', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-everolimus', 'diltiazem', 'Diltiazem', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-temsirolimus', 'diltiazem', 'Diltiazem', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-fentanyl', 'diltiazem', 'Diltiazem', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-oxycodone', 'diltiazem', 'Diltiazem', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-diltiazem', 'diltiazem', 'Diltiazem', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-sufentanil', 'diltiazem', 'Diltiazem', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-methadone_3a4', 'diltiazem', 'Diltiazem', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-diltiazem', 'diltiazem', 'Diltiazem', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-sildenafil', 'diltiazem', 'Diltiazem', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-tadalafil', 'diltiazem', 'Diltiazem', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-vardenafil', 'diltiazem', 'Diltiazem', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-diltiazem', 'diltiazem', 'Diltiazem', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-diltiazem', 'diltiazem', 'Diltiazem', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-felodipine', 'diltiazem', 'Diltiazem', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-nifedipine', 'diltiazem', 'Diltiazem', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-nisoldipine', 'diltiazem', 'Diltiazem', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-nimodipine', 'diltiazem', 'Diltiazem', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-isradipine', 'diltiazem', 'Diltiazem', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lercanidipine', 'diltiazem', 'Diltiazem', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-diltiazem', 'diltiazem', 'Diltiazem', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ergotamine', 'diltiazem', 'Diltiazem', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-diltiazem', 'diltiazem', 'Diltiazem', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-eplerenone', 'diltiazem', 'Diltiazem', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ivabradine_3a4', 'diltiazem', 'Diltiazem', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-dronedarone_3a4', 'diltiazem', 'Diltiazem', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ticagrelor_3a4', 'diltiazem', 'Diltiazem', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-diltiazem', 'diltiazem', 'Diltiazem', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-rivaroxaban_3a4', 'diltiazem', 'Diltiazem', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-imatinib', 'diltiazem', 'Diltiazem', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-diltiazem', 'diltiazem', 'Diltiazem', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-nilotinib_3a4', 'diltiazem', 'Diltiazem', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-erlotinib', 'diltiazem', 'Diltiazem', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-gefitinib', 'diltiazem', 'Diltiazem', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lapatinib_3a4', 'diltiazem', 'Diltiazem', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-diltiazem', 'diltiazem', 'Diltiazem', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-diltiazem', 'diltiazem', 'Diltiazem', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ibrutinib', 'diltiazem', 'Diltiazem', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-palbociclib', 'diltiazem', 'Diltiazem', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-venetoclax', 'diltiazem', 'Diltiazem', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-olaparib', 'diltiazem', 'Diltiazem', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ruxolitinib', 'diltiazem', 'Diltiazem', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-docetaxel', 'diltiazem', 'Diltiazem', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-paclitaxel', 'diltiazem', 'Diltiazem', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-vincristine', 'diltiazem', 'Diltiazem', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-vinblastine', 'diltiazem', 'Diltiazem', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-etoposide', 'diltiazem', 'Diltiazem', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-irinotecan', 'diltiazem', 'Diltiazem', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-maraviroc', 'diltiazem', 'Diltiazem', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-diltiazem', 'diltiazem', 'Diltiazem', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-diltiazem', 'diltiazem', 'Diltiazem', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lopinavir', 'diltiazem', 'Diltiazem', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-saquinavir', 'diltiazem', 'Diltiazem', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-quetiapine_3a4', 'diltiazem', 'Diltiazem', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lurasidone_3a4', 'diltiazem', 'Diltiazem', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-diltiazem', 'diltiazem', 'Diltiazem', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-ziprasidone_3a4', 'diltiazem', 'Diltiazem', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-trazodone_3a4', 'diltiazem', 'Diltiazem', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-vilazodone', 'diltiazem', 'Diltiazem', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-diltiazem', 'diltiazem', 'Diltiazem', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-tiagabine', 'diltiazem', 'Diltiazem', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-zonisamide', 'diltiazem', 'Diltiazem', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-zolpidem_3a4', 'diltiazem', 'Diltiazem', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-zaleplon', 'diltiazem', 'Diltiazem', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-eszopiclone_3a4', 'diltiazem', 'Diltiazem', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-suvorexant', 'diltiazem', 'Diltiazem', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-lemborexant', 'diltiazem', 'Diltiazem', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-hydrocortisone', 'diltiazem', 'Diltiazem', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-diltiazem', 'diltiazem', 'Diltiazem', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-methylprednisolone', 'diltiazem', 'Diltiazem', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-diltiazem', 'diltiazem', 'Diltiazem', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-fluticasone', 'diltiazem', 'Diltiazem', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-quinidine_3a4', 'diltiazem', 'Diltiazem', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-eletriptan', 'diltiazem', 'Diltiazem', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-diltiazem', 'diltiazem', 'Diltiazem', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-tamsulosin', 'diltiazem', 'Diltiazem', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-finasteride', 'diltiazem', 'Diltiazem', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-dutasteride', 'diltiazem', 'Diltiazem', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diltiazem-tolvaptan', 'diltiazem', 'Diltiazem', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-diltiazem', 'diltiazem', 'Diltiazem', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Diltiazem is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Diltiazem and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Diltiazem is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-simvastatin-verapamil', 'verapamil', 'Verapamil', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-verapamil', 'verapamil', 'Verapamil', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-verapamil', 'verapamil', 'Verapamil', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-verapamil', 'verapamil', 'Verapamil', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-triazolam-verapamil', 'verapamil', 'Verapamil', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-verapamil', 'verapamil', 'Verapamil', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-verapamil', 'verapamil', 'Verapamil', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-verapamil', 'verapamil', 'Verapamil', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-verapamil', 'verapamil', 'Verapamil', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tacrolimus-verapamil', 'verapamil', 'Verapamil', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sirolimus-verapamil', 'verapamil', 'Verapamil', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-verapamil', 'verapamil', 'Verapamil', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-temsirolimus-verapamil', 'verapamil', 'Verapamil', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-verapamil', 'verapamil', 'Verapamil', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-verapamil', 'verapamil', 'Verapamil', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-verapamil', 'verapamil', 'Verapamil', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sufentanil-verapamil', 'verapamil', 'Verapamil', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-verapamil', 'verapamil', 'Verapamil', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-verapamil', 'verapamil', 'Verapamil', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sildenafil-verapamil', 'verapamil', 'Verapamil', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tadalafil-verapamil', 'verapamil', 'Verapamil', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-vardenafil-verapamil', 'verapamil', 'Verapamil', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-verapamil', 'verapamil', 'Verapamil', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-verapamil', 'verapamil', 'Verapamil', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-verapamil', 'verapamil', 'Verapamil', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-verapamil', 'verapamil', 'Verapamil', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-verapamil', 'verapamil', 'Verapamil', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-verapamil', 'verapamil', 'Verapamil', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-verapamil', 'verapamil', 'Verapamil', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-verapamil', 'verapamil', 'Verapamil', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-verapamil', 'verapamil', 'Verapamil', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-verapamil', 'verapamil', 'Verapamil', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-verapamil', 'verapamil', 'Verapamil', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-verapamil', 'verapamil', 'Verapamil', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-verapamil', 'verapamil', 'Verapamil', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-verapamil', 'verapamil', 'Verapamil', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ticagrelor_3a4-verapamil', 'verapamil', 'Verapamil', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-verapamil', 'verapamil', 'Verapamil', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rivaroxaban_3a4-verapamil', 'verapamil', 'Verapamil', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-verapamil', 'verapamil', 'Verapamil', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-verapamil', 'verapamil', 'Verapamil', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-verapamil', 'verapamil', 'Verapamil', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-verapamil', 'verapamil', 'Verapamil', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-verapamil', 'verapamil', 'Verapamil', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-verapamil', 'verapamil', 'Verapamil', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-verapamil', 'verapamil', 'Verapamil', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-verapamil', 'verapamil', 'Verapamil', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-verapamil', 'verapamil', 'Verapamil', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-verapamil', 'verapamil', 'Verapamil', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-venetoclax-verapamil', 'verapamil', 'Verapamil', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-verapamil', 'verapamil', 'Verapamil', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ruxolitinib-verapamil', 'verapamil', 'Verapamil', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-verapamil', 'verapamil', 'Verapamil', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-verapamil', 'verapamil', 'Verapamil', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-vincristine', 'verapamil', 'Verapamil', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-vinblastine', 'verapamil', 'Verapamil', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-verapamil', 'verapamil', 'Verapamil', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-verapamil', 'verapamil', 'Verapamil', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-verapamil', 'verapamil', 'Verapamil', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-verapamil', 'verapamil', 'Verapamil', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-verapamil', 'verapamil', 'Verapamil', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-verapamil', 'verapamil', 'Verapamil', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-saquinavir-verapamil', 'verapamil', 'Verapamil', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-verapamil', 'verapamil', 'Verapamil', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-verapamil', 'verapamil', 'Verapamil', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-verapamil', 'verapamil', 'Verapamil', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-ziprasidone_3a4', 'verapamil', 'Verapamil', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-trazodone_3a4-verapamil', 'verapamil', 'Verapamil', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-vilazodone', 'verapamil', 'Verapamil', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-verapamil', 'verapamil', 'Verapamil', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tiagabine-verapamil', 'verapamil', 'Verapamil', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-zonisamide', 'verapamil', 'Verapamil', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-zolpidem_3a4', 'verapamil', 'Verapamil', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-verapamil-zaleplon', 'verapamil', 'Verapamil', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-verapamil', 'verapamil', 'Verapamil', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-suvorexant-verapamil', 'verapamil', 'Verapamil', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-verapamil', 'verapamil', 'Verapamil', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-verapamil', 'verapamil', 'Verapamil', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-verapamil', 'verapamil', 'Verapamil', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-verapamil', 'verapamil', 'Verapamil', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-verapamil', 'verapamil', 'Verapamil', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-verapamil', 'verapamil', 'Verapamil', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-verapamil', 'verapamil', 'Verapamil', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-verapamil', 'verapamil', 'Verapamil', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-verapamil', 'verapamil', 'Verapamil', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tamsulosin-verapamil', 'verapamil', 'Verapamil', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-verapamil', 'verapamil', 'Verapamil', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-verapamil', 'verapamil', 'Verapamil', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-tolvaptan-verapamil', 'verapamil', 'Verapamil', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-verapamil', 'verapamil', 'Verapamil', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Verapamil is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Verapamil and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Verapamil is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-simvastatin', 'grapefruit', 'Grapefruit Juice', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lovastatin', 'grapefruit', 'Grapefruit Juice', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-grapefruit', 'grapefruit', 'Grapefruit Juice', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-midazolam', 'grapefruit', 'Grapefruit Juice', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-triazolam', 'grapefruit', 'Grapefruit Juice', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-grapefruit', 'grapefruit', 'Grapefruit Juice', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-grapefruit', 'grapefruit', 'Grapefruit Juice', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-tacrolimus', 'grapefruit', 'Grapefruit Juice', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-sirolimus', 'grapefruit', 'Grapefruit Juice', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-grapefruit', 'grapefruit', 'Grapefruit Juice', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-temsirolimus', 'grapefruit', 'Grapefruit Juice', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-grapefruit', 'grapefruit', 'Grapefruit Juice', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-oxycodone', 'grapefruit', 'Grapefruit Juice', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-grapefruit', 'grapefruit', 'Grapefruit Juice', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-sufentanil', 'grapefruit', 'Grapefruit Juice', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-methadone_3a4', 'grapefruit', 'Grapefruit Juice', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-sildenafil', 'grapefruit', 'Grapefruit Juice', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-tadalafil', 'grapefruit', 'Grapefruit Juice', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-vardenafil', 'grapefruit', 'Grapefruit Juice', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-grapefruit', 'grapefruit', 'Grapefruit Juice', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-nifedipine', 'grapefruit', 'Grapefruit Juice', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-nisoldipine', 'grapefruit', 'Grapefruit Juice', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-nimodipine', 'grapefruit', 'Grapefruit Juice', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-isradipine', 'grapefruit', 'Grapefruit Juice', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lercanidipine', 'grapefruit', 'Grapefruit Juice', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-grapefruit', 'grapefruit', 'Grapefruit Juice', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-grapefruit', 'grapefruit', 'Grapefruit Juice', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-grapefruit', 'grapefruit', 'Grapefruit Juice', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-ivabradine_3a4', 'grapefruit', 'Grapefruit Juice', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-ticagrelor_3a4', 'grapefruit', 'Grapefruit Juice', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-rivaroxaban_3a4', 'grapefruit', 'Grapefruit Juice', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-imatinib', 'grapefruit', 'Grapefruit Juice', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-grapefruit', 'grapefruit', 'Grapefruit Juice', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-nilotinib_3a4', 'grapefruit', 'Grapefruit Juice', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-grapefruit', 'grapefruit', 'Grapefruit Juice', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-grapefruit', 'grapefruit', 'Grapefruit Juice', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lapatinib_3a4', 'grapefruit', 'Grapefruit Juice', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-grapefruit', 'grapefruit', 'Grapefruit Juice', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-grapefruit', 'grapefruit', 'Grapefruit Juice', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-ibrutinib', 'grapefruit', 'Grapefruit Juice', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-palbociclib', 'grapefruit', 'Grapefruit Juice', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-venetoclax', 'grapefruit', 'Grapefruit Juice', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-olaparib', 'grapefruit', 'Grapefruit Juice', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-ruxolitinib', 'grapefruit', 'Grapefruit Juice', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-grapefruit', 'grapefruit', 'Grapefruit Juice', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-paclitaxel', 'grapefruit', 'Grapefruit Juice', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-vincristine', 'grapefruit', 'Grapefruit Juice', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-vinblastine', 'grapefruit', 'Grapefruit Juice', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-grapefruit', 'grapefruit', 'Grapefruit Juice', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-irinotecan', 'grapefruit', 'Grapefruit Juice', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-maraviroc', 'grapefruit', 'Grapefruit Juice', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-grapefruit', 'grapefruit', 'Grapefruit Juice', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-grapefruit', 'grapefruit', 'Grapefruit Juice', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lopinavir', 'grapefruit', 'Grapefruit Juice', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-saquinavir', 'grapefruit', 'Grapefruit Juice', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-quetiapine_3a4', 'grapefruit', 'Grapefruit Juice', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lurasidone_3a4', 'grapefruit', 'Grapefruit Juice', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-ziprasidone_3a4', 'grapefruit', 'Grapefruit Juice', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-trazodone_3a4', 'grapefruit', 'Grapefruit Juice', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-vilazodone', 'grapefruit', 'Grapefruit Juice', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-tiagabine', 'grapefruit', 'Grapefruit Juice', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-zonisamide', 'grapefruit', 'Grapefruit Juice', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-zolpidem_3a4', 'grapefruit', 'Grapefruit Juice', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-zaleplon', 'grapefruit', 'Grapefruit Juice', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-grapefruit', 'grapefruit', 'Grapefruit Juice', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-suvorexant', 'grapefruit', 'Grapefruit Juice', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-lemborexant', 'grapefruit', 'Grapefruit Juice', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-hydrocortisone', 'grapefruit', 'Grapefruit Juice', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-grapefruit', 'grapefruit', 'Grapefruit Juice', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-methylprednisolone', 'grapefruit', 'Grapefruit Juice', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-grapefruit', 'grapefruit', 'Grapefruit Juice', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-grapefruit', 'grapefruit', 'Grapefruit Juice', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-quinidine_3a4', 'grapefruit', 'Grapefruit Juice', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-grapefruit', 'grapefruit', 'Grapefruit Juice', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-grapefruit', 'grapefruit', 'Grapefruit Juice', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-tamsulosin', 'grapefruit', 'Grapefruit Juice', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-grapefruit', 'grapefruit', 'Grapefruit Juice', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-grapefruit', 'grapefruit', 'Grapefruit Juice', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-grapefruit-tolvaptan', 'grapefruit', 'Grapefruit Juice', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-grapefruit', 'grapefruit', 'Grapefruit Juice', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Grapefruit Juice is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Grapefruit Juice and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Grapefruit Juice is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-simvastatin', 'cimetidine', 'Cimetidine', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lovastatin', 'cimetidine', 'Cimetidine', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-cimetidine', 'cimetidine', 'Cimetidine', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-midazolam', 'cimetidine', 'Cimetidine', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-triazolam', 'cimetidine', 'Cimetidine', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-cimetidine', 'cimetidine', 'Cimetidine', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-diazepam_3a4', 'cimetidine', 'Cimetidine', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-clorazepate', 'cimetidine', 'Cimetidine', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-cyclosporine', 'cimetidine', 'Cimetidine', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-tacrolimus', 'cimetidine', 'Cimetidine', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-sirolimus', 'cimetidine', 'Cimetidine', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-everolimus', 'cimetidine', 'Cimetidine', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-temsirolimus', 'cimetidine', 'Cimetidine', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-fentanyl', 'cimetidine', 'Cimetidine', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-oxycodone', 'cimetidine', 'Cimetidine', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-cimetidine', 'cimetidine', 'Cimetidine', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-sufentanil', 'cimetidine', 'Cimetidine', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-methadone_3a4', 'cimetidine', 'Cimetidine', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-cimetidine', 'cimetidine', 'Cimetidine', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-sildenafil', 'cimetidine', 'Cimetidine', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-tadalafil', 'cimetidine', 'Cimetidine', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-vardenafil', 'cimetidine', 'Cimetidine', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-cimetidine', 'cimetidine', 'Cimetidine', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-cimetidine', 'cimetidine', 'Cimetidine', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-felodipine', 'cimetidine', 'Cimetidine', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-nifedipine', 'cimetidine', 'Cimetidine', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-nisoldipine', 'cimetidine', 'Cimetidine', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-nimodipine', 'cimetidine', 'Cimetidine', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-isradipine', 'cimetidine', 'Cimetidine', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lercanidipine', 'cimetidine', 'Cimetidine', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-colchicine', 'cimetidine', 'Cimetidine', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ergotamine', 'cimetidine', 'Cimetidine', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-cimetidine', 'cimetidine', 'Cimetidine', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-eplerenone', 'cimetidine', 'Cimetidine', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ivabradine_3a4', 'cimetidine', 'Cimetidine', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-dronedarone_3a4', 'cimetidine', 'Cimetidine', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ticagrelor_3a4', 'cimetidine', 'Cimetidine', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-cimetidine', 'cimetidine', 'Cimetidine', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-rivaroxaban_3a4', 'cimetidine', 'Cimetidine', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-imatinib', 'cimetidine', 'Cimetidine', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-dasatinib', 'cimetidine', 'Cimetidine', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-nilotinib_3a4', 'cimetidine', 'Cimetidine', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-erlotinib', 'cimetidine', 'Cimetidine', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-gefitinib', 'cimetidine', 'Cimetidine', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lapatinib_3a4', 'cimetidine', 'Cimetidine', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-cimetidine', 'cimetidine', 'Cimetidine', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-cimetidine', 'cimetidine', 'Cimetidine', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ibrutinib', 'cimetidine', 'Cimetidine', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-palbociclib', 'cimetidine', 'Cimetidine', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-venetoclax', 'cimetidine', 'Cimetidine', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-olaparib', 'cimetidine', 'Cimetidine', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ruxolitinib', 'cimetidine', 'Cimetidine', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-docetaxel', 'cimetidine', 'Cimetidine', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-paclitaxel', 'cimetidine', 'Cimetidine', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-vincristine', 'cimetidine', 'Cimetidine', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-vinblastine', 'cimetidine', 'Cimetidine', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-etoposide', 'cimetidine', 'Cimetidine', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-irinotecan', 'cimetidine', 'Cimetidine', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-maraviroc', 'cimetidine', 'Cimetidine', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-cimetidine', 'cimetidine', 'Cimetidine', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-darunavir', 'cimetidine', 'Cimetidine', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lopinavir', 'cimetidine', 'Cimetidine', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-saquinavir', 'cimetidine', 'Cimetidine', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-quetiapine_3a4', 'cimetidine', 'Cimetidine', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lurasidone_3a4', 'cimetidine', 'Cimetidine', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-cimetidine', 'cimetidine', 'Cimetidine', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-ziprasidone_3a4', 'cimetidine', 'Cimetidine', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-trazodone_3a4', 'cimetidine', 'Cimetidine', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-vilazodone', 'cimetidine', 'Cimetidine', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-cimetidine', 'cimetidine', 'Cimetidine', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-tiagabine', 'cimetidine', 'Cimetidine', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-zonisamide', 'cimetidine', 'Cimetidine', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-zolpidem_3a4', 'cimetidine', 'Cimetidine', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-zaleplon', 'cimetidine', 'Cimetidine', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-eszopiclone_3a4', 'cimetidine', 'Cimetidine', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-suvorexant', 'cimetidine', 'Cimetidine', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-lemborexant', 'cimetidine', 'Cimetidine', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-hydrocortisone', 'cimetidine', 'Cimetidine', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-cimetidine', 'cimetidine', 'Cimetidine', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-methylprednisolone', 'cimetidine', 'Cimetidine', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-dexamethasone', 'cimetidine', 'Cimetidine', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-fluticasone', 'cimetidine', 'Cimetidine', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-quinidine_3a4', 'cimetidine', 'Cimetidine', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-eletriptan', 'cimetidine', 'Cimetidine', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-cimetidine', 'cimetidine', 'Cimetidine', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-tamsulosin', 'cimetidine', 'Cimetidine', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-finasteride', 'cimetidine', 'Cimetidine', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-dutasteride', 'cimetidine', 'Cimetidine', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-tolvaptan', 'cimetidine', 'Cimetidine', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cimetidine-conivaptan', 'cimetidine', 'Cimetidine', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-simvastatin', 'rifampin', 'Rifampin', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-rifampin', 'rifampin', 'Rifampin', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-rifampin', 'rifampin', 'Rifampin', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-rifampin', 'rifampin', 'Rifampin', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-triazolam', 'rifampin', 'Rifampin', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-rifampin', 'rifampin', 'Rifampin', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-rifampin', 'rifampin', 'Rifampin', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-rifampin', 'rifampin', 'Rifampin', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-rifampin', 'rifampin', 'Rifampin', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-tacrolimus', 'rifampin', 'Rifampin', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-sirolimus', 'rifampin', 'Rifampin', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-rifampin', 'rifampin', 'Rifampin', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-temsirolimus', 'rifampin', 'Rifampin', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-rifampin', 'rifampin', 'Rifampin', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-rifampin', 'rifampin', 'Rifampin', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-rifampin', 'rifampin', 'Rifampin', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-sufentanil', 'rifampin', 'Rifampin', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-rifampin', 'rifampin', 'Rifampin', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-rifampin', 'rifampin', 'Rifampin', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-sildenafil', 'rifampin', 'Rifampin', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-tadalafil', 'rifampin', 'Rifampin', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-vardenafil', 'rifampin', 'Rifampin', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-rifampin', 'rifampin', 'Rifampin', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-rifampin', 'rifampin', 'Rifampin', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-rifampin', 'rifampin', 'Rifampin', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-rifampin', 'rifampin', 'Rifampin', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-rifampin', 'rifampin', 'Rifampin', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-rifampin', 'rifampin', 'Rifampin', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-rifampin', 'rifampin', 'Rifampin', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-rifampin', 'rifampin', 'Rifampin', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-rifampin', 'rifampin', 'Rifampin', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-rifampin', 'rifampin', 'Rifampin', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-rifampin', 'rifampin', 'Rifampin', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-rifampin', 'rifampin', 'Rifampin', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-rifampin', 'rifampin', 'Rifampin', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-rifampin', 'rifampin', 'Rifampin', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-ticagrelor_3a4', 'rifampin', 'Rifampin', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-rifampin', 'rifampin', 'Rifampin', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-rivaroxaban_3a4', 'rifampin', 'Rifampin', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-rifampin', 'rifampin', 'Rifampin', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-rifampin', 'rifampin', 'Rifampin', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-rifampin', 'rifampin', 'Rifampin', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-rifampin', 'rifampin', 'Rifampin', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-rifampin', 'rifampin', 'Rifampin', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-rifampin', 'rifampin', 'Rifampin', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-rifampin', 'rifampin', 'Rifampin', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-rifampin', 'rifampin', 'Rifampin', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-rifampin', 'rifampin', 'Rifampin', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-rifampin', 'rifampin', 'Rifampin', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-venetoclax', 'rifampin', 'Rifampin', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-rifampin', 'rifampin', 'Rifampin', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-ruxolitinib', 'rifampin', 'Rifampin', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-rifampin', 'rifampin', 'Rifampin', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-rifampin', 'rifampin', 'Rifampin', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-vincristine', 'rifampin', 'Rifampin', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-vinblastine', 'rifampin', 'Rifampin', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-rifampin', 'rifampin', 'Rifampin', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-rifampin', 'rifampin', 'Rifampin', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-rifampin', 'rifampin', 'Rifampin', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-rifampin', 'rifampin', 'Rifampin', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-rifampin', 'rifampin', 'Rifampin', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-rifampin', 'rifampin', 'Rifampin', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-saquinavir', 'rifampin', 'Rifampin', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-rifampin', 'rifampin', 'Rifampin', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-rifampin', 'rifampin', 'Rifampin', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-rifampin', 'rifampin', 'Rifampin', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-ziprasidone_3a4', 'rifampin', 'Rifampin', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-trazodone_3a4', 'rifampin', 'Rifampin', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-vilazodone', 'rifampin', 'Rifampin', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-rifampin', 'rifampin', 'Rifampin', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-tiagabine', 'rifampin', 'Rifampin', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-zonisamide', 'rifampin', 'Rifampin', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-zolpidem_3a4', 'rifampin', 'Rifampin', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-zaleplon', 'rifampin', 'Rifampin', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-rifampin', 'rifampin', 'Rifampin', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-suvorexant', 'rifampin', 'Rifampin', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-rifampin', 'rifampin', 'Rifampin', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-rifampin', 'rifampin', 'Rifampin', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-rifampin', 'rifampin', 'Rifampin', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-rifampin', 'rifampin', 'Rifampin', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-rifampin', 'rifampin', 'Rifampin', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-rifampin', 'rifampin', 'Rifampin', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-rifampin', 'rifampin', 'Rifampin', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-rifampin', 'rifampin', 'Rifampin', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-rifampin', 'rifampin', 'Rifampin', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-tamsulosin', 'rifampin', 'Rifampin', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-rifampin', 'rifampin', 'Rifampin', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-rifampin', 'rifampin', 'Rifampin', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifampin-tolvaptan', 'rifampin', 'Rifampin', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-rifampin', 'rifampin', 'Rifampin', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifampin induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifampin and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifampin induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-simvastatin', 'rifabutin', 'Rifabutin', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-rifabutin', 'rifabutin', 'Rifabutin', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-rifabutin', 'rifabutin', 'Rifabutin', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-rifabutin', 'rifabutin', 'Rifabutin', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-triazolam', 'rifabutin', 'Rifabutin', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-rifabutin', 'rifabutin', 'Rifabutin', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-rifabutin', 'rifabutin', 'Rifabutin', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-rifabutin', 'rifabutin', 'Rifabutin', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-tacrolimus', 'rifabutin', 'Rifabutin', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-sirolimus', 'rifabutin', 'Rifabutin', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-rifabutin', 'rifabutin', 'Rifabutin', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-temsirolimus', 'rifabutin', 'Rifabutin', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-rifabutin', 'rifabutin', 'Rifabutin', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-rifabutin', 'rifabutin', 'Rifabutin', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-rifabutin', 'rifabutin', 'Rifabutin', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-sufentanil', 'rifabutin', 'Rifabutin', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-rifabutin', 'rifabutin', 'Rifabutin', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-sildenafil', 'rifabutin', 'Rifabutin', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-tadalafil', 'rifabutin', 'Rifabutin', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-vardenafil', 'rifabutin', 'Rifabutin', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-rifabutin', 'rifabutin', 'Rifabutin', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-rifabutin', 'rifabutin', 'Rifabutin', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-rifabutin', 'rifabutin', 'Rifabutin', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-rifabutin', 'rifabutin', 'Rifabutin', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-rifabutin', 'rifabutin', 'Rifabutin', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-rifabutin', 'rifabutin', 'Rifabutin', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-rifabutin', 'rifabutin', 'Rifabutin', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-rifabutin', 'rifabutin', 'Rifabutin', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-rifabutin', 'rifabutin', 'Rifabutin', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-rifabutin', 'rifabutin', 'Rifabutin', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-rifabutin', 'rifabutin', 'Rifabutin', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-rifabutin', 'rifabutin', 'Rifabutin', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-ticagrelor_3a4', 'rifabutin', 'Rifabutin', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-rivaroxaban_3a4', 'rifabutin', 'Rifabutin', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-rifabutin', 'rifabutin', 'Rifabutin', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-rifabutin', 'rifabutin', 'Rifabutin', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-rifabutin', 'rifabutin', 'Rifabutin', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-rifabutin', 'rifabutin', 'Rifabutin', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-rifabutin', 'rifabutin', 'Rifabutin', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-rifabutin', 'rifabutin', 'Rifabutin', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-rifabutin', 'rifabutin', 'Rifabutin', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-rifabutin', 'rifabutin', 'Rifabutin', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-venetoclax', 'rifabutin', 'Rifabutin', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-rifabutin', 'rifabutin', 'Rifabutin', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-ruxolitinib', 'rifabutin', 'Rifabutin', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-rifabutin', 'rifabutin', 'Rifabutin', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-rifabutin', 'rifabutin', 'Rifabutin', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-vincristine', 'rifabutin', 'Rifabutin', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-vinblastine', 'rifabutin', 'Rifabutin', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-rifabutin', 'rifabutin', 'Rifabutin', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-rifabutin', 'rifabutin', 'Rifabutin', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-rifabutin', 'rifabutin', 'Rifabutin', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-rifabutin', 'rifabutin', 'Rifabutin', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-rifabutin', 'rifabutin', 'Rifabutin', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-rifabutin', 'rifabutin', 'Rifabutin', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-saquinavir', 'rifabutin', 'Rifabutin', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-ziprasidone_3a4', 'rifabutin', 'Rifabutin', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-trazodone_3a4', 'rifabutin', 'Rifabutin', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-vilazodone', 'rifabutin', 'Rifabutin', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-tiagabine', 'rifabutin', 'Rifabutin', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-zonisamide', 'rifabutin', 'Rifabutin', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-zolpidem_3a4', 'rifabutin', 'Rifabutin', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-zaleplon', 'rifabutin', 'Rifabutin', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-suvorexant', 'rifabutin', 'Rifabutin', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-rifabutin', 'rifabutin', 'Rifabutin', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-rifabutin', 'rifabutin', 'Rifabutin', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-rifabutin', 'rifabutin', 'Rifabutin', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-rifabutin', 'rifabutin', 'Rifabutin', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-rifabutin', 'rifabutin', 'Rifabutin', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-rifabutin', 'rifabutin', 'Rifabutin', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-rifabutin', 'rifabutin', 'Rifabutin', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-rifabutin', 'rifabutin', 'Rifabutin', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-rifabutin', 'rifabutin', 'Rifabutin', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-tamsulosin', 'rifabutin', 'Rifabutin', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-rifabutin', 'rifabutin', 'Rifabutin', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-rifabutin', 'rifabutin', 'Rifabutin', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rifabutin-tolvaptan', 'rifabutin', 'Rifabutin', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-rifabutin', 'rifabutin', 'Rifabutin', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Rifabutin induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Rifabutin and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rifabutin induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-simvastatin', 'phenytoin', 'Phenytoin', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-phenytoin', 'phenytoin', 'Phenytoin', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-phenytoin', 'phenytoin', 'Phenytoin', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-phenytoin', 'phenytoin', 'Phenytoin', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-triazolam', 'phenytoin', 'Phenytoin', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-phenytoin', 'phenytoin', 'Phenytoin', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-phenytoin', 'phenytoin', 'Phenytoin', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-phenytoin', 'phenytoin', 'Phenytoin', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-tacrolimus', 'phenytoin', 'Phenytoin', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-sirolimus', 'phenytoin', 'Phenytoin', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-phenytoin', 'phenytoin', 'Phenytoin', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-temsirolimus', 'phenytoin', 'Phenytoin', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-phenytoin', 'phenytoin', 'Phenytoin', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-phenytoin', 'phenytoin', 'Phenytoin', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-phenytoin', 'phenytoin', 'Phenytoin', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-sufentanil', 'phenytoin', 'Phenytoin', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-phenytoin', 'phenytoin', 'Phenytoin', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-sildenafil', 'phenytoin', 'Phenytoin', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-tadalafil', 'phenytoin', 'Phenytoin', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-vardenafil', 'phenytoin', 'Phenytoin', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-phenytoin', 'phenytoin', 'Phenytoin', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-phenytoin', 'phenytoin', 'Phenytoin', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-phenytoin', 'phenytoin', 'Phenytoin', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-phenytoin', 'phenytoin', 'Phenytoin', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-phenytoin', 'phenytoin', 'Phenytoin', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-phenytoin', 'phenytoin', 'Phenytoin', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-phenytoin', 'phenytoin', 'Phenytoin', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-phenytoin', 'phenytoin', 'Phenytoin', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-phenytoin', 'phenytoin', 'Phenytoin', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-phenytoin', 'phenytoin', 'Phenytoin', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-phenytoin', 'phenytoin', 'Phenytoin', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-phenytoin', 'phenytoin', 'Phenytoin', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-ticagrelor_3a4', 'phenytoin', 'Phenytoin', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-rivaroxaban_3a4', 'phenytoin', 'Phenytoin', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-phenytoin', 'phenytoin', 'Phenytoin', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-phenytoin', 'phenytoin', 'Phenytoin', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-phenytoin', 'phenytoin', 'Phenytoin', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-phenytoin', 'phenytoin', 'Phenytoin', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-phenytoin', 'phenytoin', 'Phenytoin', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-phenytoin', 'phenytoin', 'Phenytoin', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-phenytoin', 'phenytoin', 'Phenytoin', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-phenytoin', 'phenytoin', 'Phenytoin', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-venetoclax', 'phenytoin', 'Phenytoin', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-phenytoin', 'phenytoin', 'Phenytoin', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-ruxolitinib', 'phenytoin', 'Phenytoin', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-phenytoin', 'phenytoin', 'Phenytoin', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-phenytoin', 'phenytoin', 'Phenytoin', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-vincristine', 'phenytoin', 'Phenytoin', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-vinblastine', 'phenytoin', 'Phenytoin', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-phenytoin', 'phenytoin', 'Phenytoin', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-phenytoin', 'phenytoin', 'Phenytoin', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-phenytoin', 'phenytoin', 'Phenytoin', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-phenytoin', 'phenytoin', 'Phenytoin', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-phenytoin', 'phenytoin', 'Phenytoin', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-phenytoin', 'phenytoin', 'Phenytoin', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-saquinavir', 'phenytoin', 'Phenytoin', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-quetiapine_3a4', 'phenytoin', 'Phenytoin', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-ziprasidone_3a4', 'phenytoin', 'Phenytoin', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-trazodone_3a4', 'phenytoin', 'Phenytoin', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-vilazodone', 'phenytoin', 'Phenytoin', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-tiagabine', 'phenytoin', 'Phenytoin', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-zonisamide', 'phenytoin', 'Phenytoin', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-zolpidem_3a4', 'phenytoin', 'Phenytoin', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-zaleplon', 'phenytoin', 'Phenytoin', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-phenytoin', 'phenytoin', 'Phenytoin', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-suvorexant', 'phenytoin', 'Phenytoin', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-phenytoin', 'phenytoin', 'Phenytoin', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-phenytoin', 'phenytoin', 'Phenytoin', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-phenytoin', 'phenytoin', 'Phenytoin', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-phenytoin', 'phenytoin', 'Phenytoin', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-phenytoin', 'phenytoin', 'Phenytoin', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-phenytoin', 'phenytoin', 'Phenytoin', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-quinidine_3a4', 'phenytoin', 'Phenytoin', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-phenytoin', 'phenytoin', 'Phenytoin', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-phenytoin', 'phenytoin', 'Phenytoin', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-tamsulosin', 'phenytoin', 'Phenytoin', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-phenytoin', 'phenytoin', 'Phenytoin', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-phenytoin', 'phenytoin', 'Phenytoin', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenytoin-tolvaptan', 'phenytoin', 'Phenytoin', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-phenytoin', 'phenytoin', 'Phenytoin', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenytoin induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenytoin and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenytoin induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-simvastatin', 'carbamazepine', 'Carbamazepine', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lovastatin', 'carbamazepine', 'Carbamazepine', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-carbamazepine', 'carbamazepine', 'Carbamazepine', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-midazolam', 'carbamazepine', 'Carbamazepine', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-triazolam', 'carbamazepine', 'Carbamazepine', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-carbamazepine', 'carbamazepine', 'Carbamazepine', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-diazepam_3a4', 'carbamazepine', 'Carbamazepine', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-clorazepate', 'carbamazepine', 'Carbamazepine', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-cyclosporine', 'carbamazepine', 'Carbamazepine', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-tacrolimus', 'carbamazepine', 'Carbamazepine', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-sirolimus', 'carbamazepine', 'Carbamazepine', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-everolimus', 'carbamazepine', 'Carbamazepine', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-temsirolimus', 'carbamazepine', 'Carbamazepine', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-fentanyl', 'carbamazepine', 'Carbamazepine', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-oxycodone', 'carbamazepine', 'Carbamazepine', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-carbamazepine', 'carbamazepine', 'Carbamazepine', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-sufentanil', 'carbamazepine', 'Carbamazepine', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-methadone_3a4', 'carbamazepine', 'Carbamazepine', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-carbamazepine', 'carbamazepine', 'Carbamazepine', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-sildenafil', 'carbamazepine', 'Carbamazepine', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-tadalafil', 'carbamazepine', 'Carbamazepine', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-vardenafil', 'carbamazepine', 'Carbamazepine', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-carbamazepine', 'carbamazepine', 'Carbamazepine', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-carbamazepine', 'carbamazepine', 'Carbamazepine', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-felodipine', 'carbamazepine', 'Carbamazepine', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-nifedipine', 'carbamazepine', 'Carbamazepine', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-nisoldipine', 'carbamazepine', 'Carbamazepine', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-nimodipine', 'carbamazepine', 'Carbamazepine', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-isradipine', 'carbamazepine', 'Carbamazepine', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lercanidipine', 'carbamazepine', 'Carbamazepine', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-colchicine', 'carbamazepine', 'Carbamazepine', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ergotamine', 'carbamazepine', 'Carbamazepine', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-carbamazepine', 'carbamazepine', 'Carbamazepine', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-eplerenone', 'carbamazepine', 'Carbamazepine', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ivabradine_3a4', 'carbamazepine', 'Carbamazepine', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-dronedarone_3a4', 'carbamazepine', 'Carbamazepine', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ticagrelor_3a4', 'carbamazepine', 'Carbamazepine', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-carbamazepine', 'carbamazepine', 'Carbamazepine', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-rivaroxaban_3a4', 'carbamazepine', 'Carbamazepine', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-imatinib', 'carbamazepine', 'Carbamazepine', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-dasatinib', 'carbamazepine', 'Carbamazepine', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-nilotinib_3a4', 'carbamazepine', 'Carbamazepine', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-erlotinib', 'carbamazepine', 'Carbamazepine', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-gefitinib', 'carbamazepine', 'Carbamazepine', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lapatinib_3a4', 'carbamazepine', 'Carbamazepine', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-carbamazepine', 'carbamazepine', 'Carbamazepine', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-carbamazepine', 'carbamazepine', 'Carbamazepine', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ibrutinib', 'carbamazepine', 'Carbamazepine', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-palbociclib', 'carbamazepine', 'Carbamazepine', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-venetoclax', 'carbamazepine', 'Carbamazepine', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-olaparib', 'carbamazepine', 'Carbamazepine', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ruxolitinib', 'carbamazepine', 'Carbamazepine', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-docetaxel', 'carbamazepine', 'Carbamazepine', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-paclitaxel', 'carbamazepine', 'Carbamazepine', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-vincristine', 'carbamazepine', 'Carbamazepine', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-vinblastine', 'carbamazepine', 'Carbamazepine', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-etoposide', 'carbamazepine', 'Carbamazepine', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-irinotecan', 'carbamazepine', 'Carbamazepine', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-maraviroc', 'carbamazepine', 'Carbamazepine', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-carbamazepine', 'carbamazepine', 'Carbamazepine', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-darunavir', 'carbamazepine', 'Carbamazepine', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lopinavir', 'carbamazepine', 'Carbamazepine', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-saquinavir', 'carbamazepine', 'Carbamazepine', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-quetiapine_3a4', 'carbamazepine', 'Carbamazepine', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lurasidone_3a4', 'carbamazepine', 'Carbamazepine', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-carbamazepine', 'carbamazepine', 'Carbamazepine', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-ziprasidone_3a4', 'carbamazepine', 'Carbamazepine', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-trazodone_3a4', 'carbamazepine', 'Carbamazepine', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-vilazodone', 'carbamazepine', 'Carbamazepine', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-carbamazepine_3a4', 'carbamazepine', 'Carbamazepine', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-tiagabine', 'carbamazepine', 'Carbamazepine', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-zonisamide', 'carbamazepine', 'Carbamazepine', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-zolpidem_3a4', 'carbamazepine', 'Carbamazepine', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-zaleplon', 'carbamazepine', 'Carbamazepine', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-eszopiclone_3a4', 'carbamazepine', 'Carbamazepine', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-suvorexant', 'carbamazepine', 'Carbamazepine', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-lemborexant', 'carbamazepine', 'Carbamazepine', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-hydrocortisone', 'carbamazepine', 'Carbamazepine', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-carbamazepine', 'carbamazepine', 'Carbamazepine', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-methylprednisolone', 'carbamazepine', 'Carbamazepine', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-dexamethasone', 'carbamazepine', 'Carbamazepine', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-fluticasone', 'carbamazepine', 'Carbamazepine', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-quinidine_3a4', 'carbamazepine', 'Carbamazepine', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-eletriptan', 'carbamazepine', 'Carbamazepine', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-carbamazepine', 'carbamazepine', 'Carbamazepine', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-tamsulosin', 'carbamazepine', 'Carbamazepine', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-finasteride', 'carbamazepine', 'Carbamazepine', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-dutasteride', 'carbamazepine', 'Carbamazepine', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-tolvaptan', 'carbamazepine', 'Carbamazepine', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine-conivaptan', 'carbamazepine', 'Carbamazepine', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Carbamazepine induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Carbamazepine and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Carbamazepine induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-simvastatin', 'phenobarbital', 'Phenobarbital', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-phenobarbital', 'phenobarbital', 'Phenobarbital', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-phenobarbital', 'phenobarbital', 'Phenobarbital', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-triazolam', 'phenobarbital', 'Phenobarbital', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-phenobarbital', 'phenobarbital', 'Phenobarbital', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-phenobarbital', 'phenobarbital', 'Phenobarbital', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-tacrolimus', 'phenobarbital', 'Phenobarbital', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-sirolimus', 'phenobarbital', 'Phenobarbital', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-phenobarbital', 'phenobarbital', 'Phenobarbital', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-temsirolimus', 'phenobarbital', 'Phenobarbital', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-phenobarbital', 'phenobarbital', 'Phenobarbital', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-phenobarbital', 'phenobarbital', 'Phenobarbital', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-sufentanil', 'phenobarbital', 'Phenobarbital', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-sildenafil', 'phenobarbital', 'Phenobarbital', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-tadalafil', 'phenobarbital', 'Phenobarbital', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-vardenafil', 'phenobarbital', 'Phenobarbital', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-phenobarbital', 'phenobarbital', 'Phenobarbital', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-phenobarbital', 'phenobarbital', 'Phenobarbital', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-ticagrelor_3a4', 'phenobarbital', 'Phenobarbital', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-rivaroxaban_3a4', 'phenobarbital', 'Phenobarbital', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-venetoclax', 'phenobarbital', 'Phenobarbital', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-phenobarbital', 'phenobarbital', 'Phenobarbital', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-ruxolitinib', 'phenobarbital', 'Phenobarbital', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-phenobarbital', 'phenobarbital', 'Phenobarbital', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-phenobarbital', 'phenobarbital', 'Phenobarbital', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-vincristine', 'phenobarbital', 'Phenobarbital', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-vinblastine', 'phenobarbital', 'Phenobarbital', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-phenobarbital', 'phenobarbital', 'Phenobarbital', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-phenobarbital', 'phenobarbital', 'Phenobarbital', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-phenobarbital', 'phenobarbital', 'Phenobarbital', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-phenobarbital', 'phenobarbital', 'Phenobarbital', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-phenobarbital', 'phenobarbital', 'Phenobarbital', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-saquinavir', 'phenobarbital', 'Phenobarbital', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-quetiapine_3a4', 'phenobarbital', 'Phenobarbital', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-ziprasidone_3a4', 'phenobarbital', 'Phenobarbital', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-trazodone_3a4', 'phenobarbital', 'Phenobarbital', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-vilazodone', 'phenobarbital', 'Phenobarbital', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-tiagabine', 'phenobarbital', 'Phenobarbital', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-zonisamide', 'phenobarbital', 'Phenobarbital', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-zolpidem_3a4', 'phenobarbital', 'Phenobarbital', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-zaleplon', 'phenobarbital', 'Phenobarbital', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-phenobarbital', 'phenobarbital', 'Phenobarbital', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-suvorexant', 'phenobarbital', 'Phenobarbital', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-phenobarbital', 'phenobarbital', 'Phenobarbital', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-phenobarbital', 'phenobarbital', 'Phenobarbital', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-phenobarbital', 'phenobarbital', 'Phenobarbital', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-quinidine_3a4', 'phenobarbital', 'Phenobarbital', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-phenobarbital', 'phenobarbital', 'Phenobarbital', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-phenobarbital', 'phenobarbital', 'Phenobarbital', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-tamsulosin', 'phenobarbital', 'Phenobarbital', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-phenobarbital', 'phenobarbital', 'Phenobarbital', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-phenobarbital', 'phenobarbital', 'Phenobarbital', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-phenobarbital-tolvaptan', 'phenobarbital', 'Phenobarbital', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-phenobarbital', 'phenobarbital', 'Phenobarbital', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'Phenobarbital induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Phenobarbital and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Phenobarbital induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-simvastatin-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-triazolam', 'st_johns_wort', 'St. John''s Wort', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-tacrolimus', 'st_johns_wort', 'St. John''s Wort', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sirolimus-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-temsirolimus', 'st_johns_wort', 'St. John''s Wort', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-oxycodone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-sufentanil', 'st_johns_wort', 'St. John''s Wort', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-sildenafil-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-tadalafil', 'st_johns_wort', 'St. John''s Wort', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-vardenafil', 'st_johns_wort', 'St. John''s Wort', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nifedipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nisoldipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nimodipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-ticagrelor_3a4', 'st_johns_wort', 'St. John''s Wort', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-rivaroxaban_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-nilotinib_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-palbociclib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-venetoclax', 'st_johns_wort', 'St. John''s Wort', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-olaparib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ruxolitinib-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-paclitaxel-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-vincristine', 'st_johns_wort', 'St. John''s Wort', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-vinblastine', 'st_johns_wort', 'St. John''s Wort', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-saquinavir-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quetiapine_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-ziprasidone_3a4', 'st_johns_wort', 'St. John''s Wort', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-trazodone_3a4', 'st_johns_wort', 'St. John''s Wort', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-vilazodone', 'st_johns_wort', 'St. John''s Wort', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-tiagabine', 'st_johns_wort', 'St. John''s Wort', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-zonisamide', 'st_johns_wort', 'St. John''s Wort', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-zolpidem_3a4', 'st_johns_wort', 'St. John''s Wort', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-zaleplon', 'st_johns_wort', 'St. John''s Wort', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-suvorexant', 'st_johns_wort', 'St. John''s Wort', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-quinidine_3a4-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-tamsulosin', 'st_johns_wort', 'St. John''s Wort', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-st_johns_wort-tolvaptan', 'st_johns_wort', 'St. John''s Wort', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-st_johns_wort', 'st_johns_wort', 'St. John''s Wort', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'major', 'established',
    'St. John''s Wort induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'St. John''s Wort and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'St. John''s Wort induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-simvastatin', 'efavirenz', 'Efavirenz', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate',
    'Increased Simvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Simvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lovastatin', 'efavirenz', 'Efavirenz', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate',
    'Increased Lovastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lovastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-efavirenz', 'efavirenz', 'Efavirenz', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate',
    'Increased Atorvastatin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atorvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-midazolam', 'efavirenz', 'Efavirenz', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate',
    'Increased Midazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Midazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-triazolam', 'efavirenz', 'Efavirenz', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate',
    'Increased Triazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Triazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-efavirenz', 'efavirenz', 'Efavirenz', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate',
    'Increased Alprazolam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alprazolam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-efavirenz', 'efavirenz', 'Efavirenz', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate',
    'Increased Diazepam plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-efavirenz', 'efavirenz', 'Efavirenz', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate',
    'Increased Clorazepate plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Clorazepate toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-efavirenz', 'efavirenz', 'Efavirenz', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate',
    'Increased Cyclosporine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cyclosporine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-tacrolimus', 'efavirenz', 'Efavirenz', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate',
    'Increased Tacrolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tacrolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-sirolimus', 'efavirenz', 'Efavirenz', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate',
    'Increased Sirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-everolimus', 'efavirenz', 'Efavirenz', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate',
    'Increased Everolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Everolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-temsirolimus', 'efavirenz', 'Efavirenz', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate',
    'Increased Temsirolimus plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Temsirolimus toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-fentanyl', 'efavirenz', 'Efavirenz', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate',
    'Increased Fentanyl plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fentanyl toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-oxycodone', 'efavirenz', 'Efavirenz', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-efavirenz', 'efavirenz', 'Efavirenz', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate',
    'Increased Alfentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-sufentanil', 'efavirenz', 'Efavirenz', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate',
    'Increased Sufentanil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sufentanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-methadone_3a4', 'efavirenz', 'Efavirenz', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate',
    'Increased Methadone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methadone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-efavirenz', 'efavirenz', 'Efavirenz', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate',
    'Increased Buprenorphine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buprenorphine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-sildenafil', 'efavirenz', 'Efavirenz', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate',
    'Increased Sildenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Sildenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-tadalafil', 'efavirenz', 'Efavirenz', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate',
    'Increased Tadalafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tadalafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-vardenafil', 'efavirenz', 'Efavirenz', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate',
    'Increased Vardenafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vardenafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-efavirenz', 'efavirenz', 'Efavirenz', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate',
    'Increased Avanafil plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Avanafil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-efavirenz', 'efavirenz', 'Efavirenz', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate',
    'Increased Amlodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Amlodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-felodipine', 'efavirenz', 'Efavirenz', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate',
    'Increased Felodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Felodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-nifedipine', 'efavirenz', 'Efavirenz', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate',
    'Increased Nifedipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nifedipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-nisoldipine', 'efavirenz', 'Efavirenz', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate',
    'Increased Nisoldipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nisoldipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-nimodipine', 'efavirenz', 'Efavirenz', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate',
    'Increased Nimodipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nimodipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-isradipine', 'efavirenz', 'Efavirenz', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate',
    'Increased Isradipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Isradipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lercanidipine', 'efavirenz', 'Efavirenz', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate',
    'Increased Lercanidipine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lercanidipine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-efavirenz', 'efavirenz', 'Efavirenz', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate',
    'Increased Colchicine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Colchicine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ergotamine', 'efavirenz', 'Efavirenz', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate',
    'Increased Ergotamine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ergotamine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-efavirenz', 'efavirenz', 'Efavirenz', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate',
    'Increased Buspirone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Buspirone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-eplerenone', 'efavirenz', 'Efavirenz', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate',
    'Increased Eplerenone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eplerenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ivabradine_3a4', 'efavirenz', 'Efavirenz', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate',
    'Increased Ivabradine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ivabradine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-efavirenz', 'efavirenz', 'Efavirenz', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate',
    'Increased Dronedarone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dronedarone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ticagrelor_3a4', 'efavirenz', 'Efavirenz', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate',
    'Increased Ticagrelor plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ticagrelor toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-efavirenz', 'efavirenz', 'Efavirenz', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate',
    'Increased Apixaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Apixaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-rivaroxaban_3a4', 'efavirenz', 'Efavirenz', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate',
    'Increased Rivaroxaban plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Rivaroxaban toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-imatinib', 'efavirenz', 'Efavirenz', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate',
    'Increased Imatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Imatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-efavirenz', 'efavirenz', 'Efavirenz', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate',
    'Increased Dasatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dasatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-nilotinib_3a4', 'efavirenz', 'Efavirenz', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate',
    'Increased Nilotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Nilotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-erlotinib', 'efavirenz', 'Efavirenz', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate',
    'Increased Erlotinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Erlotinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-gefitinib', 'efavirenz', 'Efavirenz', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate',
    'Increased Gefitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Gefitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lapatinib_3a4', 'efavirenz', 'Efavirenz', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate',
    'Increased Lapatinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lapatinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-efavirenz', 'efavirenz', 'Efavirenz', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate',
    'Increased Axitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Axitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-efavirenz', 'efavirenz', 'Efavirenz', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate',
    'Increased Cabozantinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Cabozantinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ibrutinib', 'efavirenz', 'Efavirenz', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate',
    'Increased Ibrutinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ibrutinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-palbociclib', 'efavirenz', 'Efavirenz', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate',
    'Increased Palbociclib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Palbociclib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-venetoclax', 'efavirenz', 'Efavirenz', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate',
    'Increased Venetoclax plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Venetoclax toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-olaparib', 'efavirenz', 'Efavirenz', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate',
    'Increased Olaparib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Olaparib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ruxolitinib', 'efavirenz', 'Efavirenz', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate',
    'Increased Ruxolitinib plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ruxolitinib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-efavirenz', 'efavirenz', 'Efavirenz', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate',
    'Increased Docetaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Docetaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-paclitaxel', 'efavirenz', 'Efavirenz', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate',
    'Increased Paclitaxel plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Paclitaxel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-vincristine', 'efavirenz', 'Efavirenz', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate',
    'Increased Vincristine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vincristine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-vinblastine', 'efavirenz', 'Efavirenz', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate',
    'Increased Vinblastine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vinblastine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-etoposide', 'efavirenz', 'Efavirenz', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate',
    'Increased Etoposide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Etoposide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-irinotecan', 'efavirenz', 'Efavirenz', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate',
    'Increased Irinotecan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Irinotecan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-maraviroc', 'efavirenz', 'Efavirenz', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate',
    'Increased Maraviroc plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Maraviroc toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-efavirenz', 'efavirenz', 'Efavirenz', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate',
    'Increased Atazanavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Atazanavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-efavirenz', 'efavirenz', 'Efavirenz', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate',
    'Increased Darunavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Darunavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lopinavir', 'efavirenz', 'Efavirenz', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate',
    'Increased Lopinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lopinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-saquinavir', 'efavirenz', 'Efavirenz', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate',
    'Increased Saquinavir plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Saquinavir toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-quetiapine_3a4', 'efavirenz', 'Efavirenz', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate',
    'Increased Quetiapine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quetiapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lurasidone_3a4', 'efavirenz', 'Efavirenz', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate',
    'Increased Lurasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lurasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-efavirenz', 'efavirenz', 'Efavirenz', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-ziprasidone_3a4', 'efavirenz', 'Efavirenz', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate',
    'Increased Ziprasidone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Ziprasidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-trazodone_3a4', 'efavirenz', 'Efavirenz', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate',
    'Increased Trazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Trazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-vilazodone', 'efavirenz', 'Efavirenz', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate',
    'Increased Vilazodone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Vilazodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-efavirenz', 'efavirenz', 'Efavirenz', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate',
    'Increased Carbamazepine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Carbamazepine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-tiagabine', 'efavirenz', 'Efavirenz', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate',
    'Increased Tiagabine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tiagabine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-zonisamide', 'efavirenz', 'Efavirenz', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate',
    'Increased Zonisamide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zonisamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-zolpidem_3a4', 'efavirenz', 'Efavirenz', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate',
    'Increased Zolpidem plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zolpidem toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-zaleplon', 'efavirenz', 'Efavirenz', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate',
    'Increased Zaleplon plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Zaleplon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-eszopiclone_3a4', 'efavirenz', 'Efavirenz', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate',
    'Increased Eszopiclone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eszopiclone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-suvorexant', 'efavirenz', 'Efavirenz', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate',
    'Increased Suvorexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Suvorexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-lemborexant', 'efavirenz', 'Efavirenz', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate',
    'Increased Lemborexant plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Lemborexant toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-hydrocortisone', 'efavirenz', 'Efavirenz', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate',
    'Increased Hydrocortisone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Hydrocortisone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-efavirenz', 'efavirenz', 'Efavirenz', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate',
    'Increased Budesonide plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Budesonide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-methylprednisolone', 'efavirenz', 'Efavirenz', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate',
    'Increased Methylprednisolone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Methylprednisolone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-efavirenz', 'efavirenz', 'Efavirenz', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate',
    'Increased Dexamethasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dexamethasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-fluticasone', 'efavirenz', 'Efavirenz', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate',
    'Increased Fluticasone plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Fluticasone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-quinidine_3a4', 'efavirenz', 'Efavirenz', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate',
    'Increased Quinidine plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Quinidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-eletriptan', 'efavirenz', 'Efavirenz', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate',
    'Increased Eletriptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Eletriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-efavirenz', 'efavirenz', 'Efavirenz', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate',
    'Increased Alfuzosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Alfuzosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-tamsulosin', 'efavirenz', 'Efavirenz', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate',
    'Increased Tamsulosin plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tamsulosin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-finasteride', 'efavirenz', 'Efavirenz', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate',
    'Increased Finasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Finasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-efavirenz', 'efavirenz', 'Efavirenz', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate',
    'Increased Dutasteride plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Dutasteride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-efavirenz-tolvaptan', 'efavirenz', 'Efavirenz', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate',
    'Increased Tolvaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Tolvaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-efavirenz', 'efavirenz', 'Efavirenz', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'moderate', 'established',
    'Efavirenz is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate',
    'Increased Conivaptan plasma levels due to reduced CYP3A4 metabolism; potential for toxicity',
    'Monitor for Conivaptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Efavirenz and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Efavirenz is a moderate CYP3A4 inhibitor; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-simvastatin', 'modafinil', 'Modafinil', 'simvastatin', 'Simvastatin',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Simvastatin is a CYP3A4 substrate',
    'Decreased Simvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Simvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Simvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Simvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lovastatin-modafinil', 'modafinil', 'Modafinil', 'lovastatin', 'Lovastatin',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lovastatin is a CYP3A4 substrate',
    'Decreased Lovastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lovastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lovastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lovastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atorvastatin-modafinil', 'modafinil', 'Modafinil', 'atorvastatin', 'Atorvastatin',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Atorvastatin is a CYP3A4 substrate',
    'Decreased Atorvastatin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atorvastatin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Atorvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Atorvastatin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-midazolam-modafinil', 'modafinil', 'Modafinil', 'midazolam', 'Midazolam',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Midazolam is a CYP3A4 substrate',
    'Decreased Midazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Midazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Midazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Midazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-triazolam', 'modafinil', 'Modafinil', 'triazolam', 'Triazolam',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Triazolam is a CYP3A4 substrate',
    'Decreased Triazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Triazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Triazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Triazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alprazolam-modafinil', 'modafinil', 'Modafinil', 'alprazolam', 'Alprazolam',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Alprazolam is a CYP3A4 substrate',
    'Decreased Alprazolam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alprazolam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Alprazolam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Alprazolam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-diazepam_3a4-modafinil', 'modafinil', 'Modafinil', 'diazepam_3a4', 'Diazepam',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Diazepam is a CYP3A4 substrate',
    'Decreased Diazepam plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Diazepam efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Diazepam is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-clorazepate-modafinil', 'modafinil', 'Modafinil', 'clorazepate', 'Clorazepate',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Clorazepate is a CYP3A4 substrate',
    'Decreased Clorazepate plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Clorazepate efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Clorazepate FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Clorazepate is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cyclosporine-modafinil', 'modafinil', 'Modafinil', 'cyclosporine', 'Cyclosporine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Cyclosporine is a CYP3A4 substrate',
    'Decreased Cyclosporine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cyclosporine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Cyclosporine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Cyclosporine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-tacrolimus', 'modafinil', 'Modafinil', 'tacrolimus', 'Tacrolimus',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Tacrolimus is a CYP3A4 substrate',
    'Decreased Tacrolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tacrolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Tacrolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Tacrolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-sirolimus', 'modafinil', 'Modafinil', 'sirolimus', 'Sirolimus',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Sirolimus is a CYP3A4 substrate',
    'Decreased Sirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Sirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Sirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-everolimus-modafinil', 'modafinil', 'Modafinil', 'everolimus', 'Everolimus',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Everolimus is a CYP3A4 substrate',
    'Decreased Everolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Everolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Everolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Everolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-temsirolimus', 'modafinil', 'Modafinil', 'temsirolimus', 'Temsirolimus',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Temsirolimus is a CYP3A4 substrate',
    'Decreased Temsirolimus plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Temsirolimus efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Temsirolimus FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Temsirolimus is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fentanyl-modafinil', 'modafinil', 'Modafinil', 'fentanyl', 'Fentanyl',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Fentanyl is a CYP3A4 substrate',
    'Decreased Fentanyl plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fentanyl efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Fentanyl FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Fentanyl is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-oxycodone', 'modafinil', 'Modafinil', 'oxycodone', 'Oxycodone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Oxycodone is a CYP3A4 substrate',
    'Decreased Oxycodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Oxycodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Oxycodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfentanil-modafinil', 'modafinil', 'Modafinil', 'alfentanil', 'Alfentanil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Alfentanil is a CYP3A4 substrate',
    'Decreased Alfentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Alfentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Alfentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-sufentanil', 'modafinil', 'Modafinil', 'sufentanil', 'Sufentanil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Sufentanil is a CYP3A4 substrate',
    'Decreased Sufentanil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sufentanil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Sufentanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Sufentanil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methadone_3a4-modafinil', 'modafinil', 'Modafinil', 'methadone_3a4', 'Methadone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Methadone is a CYP3A4 substrate',
    'Decreased Methadone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methadone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Methadone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Methadone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buprenorphine-modafinil', 'modafinil', 'Modafinil', 'buprenorphine', 'Buprenorphine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Buprenorphine is a CYP3A4 substrate',
    'Decreased Buprenorphine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buprenorphine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Buprenorphine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Buprenorphine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-sildenafil', 'modafinil', 'Modafinil', 'sildenafil', 'Sildenafil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Sildenafil is a CYP3A4 substrate',
    'Decreased Sildenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Sildenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Sildenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Sildenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-tadalafil', 'modafinil', 'Modafinil', 'tadalafil', 'Tadalafil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Tadalafil is a CYP3A4 substrate',
    'Decreased Tadalafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tadalafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Tadalafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Tadalafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-vardenafil', 'modafinil', 'Modafinil', 'vardenafil', 'Vardenafil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Vardenafil is a CYP3A4 substrate',
    'Decreased Vardenafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vardenafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Vardenafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Vardenafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-avanafil-modafinil', 'modafinil', 'Modafinil', 'avanafil', 'Avanafil',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Avanafil is a CYP3A4 substrate',
    'Decreased Avanafil plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Avanafil efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Avanafil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Avanafil is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-amlodipine-modafinil', 'modafinil', 'Modafinil', 'amlodipine', 'Amlodipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Amlodipine is a CYP3A4 substrate',
    'Decreased Amlodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Amlodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Amlodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Amlodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-felodipine-modafinil', 'modafinil', 'Modafinil', 'felodipine', 'Felodipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Felodipine is a CYP3A4 substrate',
    'Decreased Felodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Felodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Felodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Felodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-nifedipine', 'modafinil', 'Modafinil', 'nifedipine', 'Nifedipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Nifedipine is a CYP3A4 substrate',
    'Decreased Nifedipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nifedipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Nifedipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Nifedipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-nisoldipine', 'modafinil', 'Modafinil', 'nisoldipine', 'Nisoldipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Nisoldipine is a CYP3A4 substrate',
    'Decreased Nisoldipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nisoldipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Nisoldipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Nisoldipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-nimodipine', 'modafinil', 'Modafinil', 'nimodipine', 'Nimodipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Nimodipine is a CYP3A4 substrate',
    'Decreased Nimodipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nimodipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Nimodipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Nimodipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-isradipine-modafinil', 'modafinil', 'Modafinil', 'isradipine', 'Isradipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Isradipine is a CYP3A4 substrate',
    'Decreased Isradipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Isradipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Isradipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Isradipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lercanidipine-modafinil', 'modafinil', 'Modafinil', 'lercanidipine', 'Lercanidipine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lercanidipine is a CYP3A4 substrate',
    'Decreased Lercanidipine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lercanidipine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lercanidipine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lercanidipine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-colchicine-modafinil', 'modafinil', 'Modafinil', 'colchicine', 'Colchicine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Colchicine is a CYP3A4 substrate',
    'Decreased Colchicine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Colchicine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Colchicine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Colchicine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ergotamine-modafinil', 'modafinil', 'Modafinil', 'ergotamine', 'Ergotamine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ergotamine is a CYP3A4 substrate',
    'Decreased Ergotamine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ergotamine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ergotamine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ergotamine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-buspirone-modafinil', 'modafinil', 'Modafinil', 'buspirone', 'Buspirone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Buspirone is a CYP3A4 substrate',
    'Decreased Buspirone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Buspirone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Buspirone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Buspirone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eplerenone-modafinil', 'modafinil', 'Modafinil', 'eplerenone', 'Eplerenone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Eplerenone is a CYP3A4 substrate',
    'Decreased Eplerenone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eplerenone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Eplerenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Eplerenone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ivabradine_3a4-modafinil', 'modafinil', 'Modafinil', 'ivabradine_3a4', 'Ivabradine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ivabradine is a CYP3A4 substrate',
    'Decreased Ivabradine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ivabradine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ivabradine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ivabradine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dronedarone_3a4-modafinil', 'modafinil', 'Modafinil', 'dronedarone_3a4', 'Dronedarone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Dronedarone is a CYP3A4 substrate',
    'Decreased Dronedarone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dronedarone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Dronedarone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Dronedarone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-ticagrelor_3a4', 'modafinil', 'Modafinil', 'ticagrelor_3a4', 'Ticagrelor',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ticagrelor is a CYP3A4 substrate',
    'Decreased Ticagrelor plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ticagrelor efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ticagrelor FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ticagrelor is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-apixaban_3a4-modafinil', 'modafinil', 'Modafinil', 'apixaban_3a4', 'Apixaban',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Apixaban is a CYP3A4 substrate',
    'Decreased Apixaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Apixaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Apixaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Apixaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-rivaroxaban_3a4', 'modafinil', 'Modafinil', 'rivaroxaban_3a4', 'Rivaroxaban',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Rivaroxaban is a CYP3A4 substrate',
    'Decreased Rivaroxaban plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Rivaroxaban efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Rivaroxaban FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Rivaroxaban is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-imatinib-modafinil', 'modafinil', 'Modafinil', 'imatinib', 'Imatinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Imatinib is a CYP3A4 substrate',
    'Decreased Imatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Imatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Imatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Imatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dasatinib-modafinil', 'modafinil', 'Modafinil', 'dasatinib', 'Dasatinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Dasatinib is a CYP3A4 substrate',
    'Decreased Dasatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dasatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Dasatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Dasatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-nilotinib_3a4', 'modafinil', 'Modafinil', 'nilotinib_3a4', 'Nilotinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Nilotinib is a CYP3A4 substrate',
    'Decreased Nilotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Nilotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Nilotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Nilotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-erlotinib-modafinil', 'modafinil', 'Modafinil', 'erlotinib', 'Erlotinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Erlotinib is a CYP3A4 substrate',
    'Decreased Erlotinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Erlotinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Erlotinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Erlotinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-gefitinib-modafinil', 'modafinil', 'Modafinil', 'gefitinib', 'Gefitinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Gefitinib is a CYP3A4 substrate',
    'Decreased Gefitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Gefitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Gefitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Gefitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lapatinib_3a4-modafinil', 'modafinil', 'Modafinil', 'lapatinib_3a4', 'Lapatinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lapatinib is a CYP3A4 substrate',
    'Decreased Lapatinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lapatinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lapatinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lapatinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-axitinib-modafinil', 'modafinil', 'Modafinil', 'axitinib', 'Axitinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Axitinib is a CYP3A4 substrate',
    'Decreased Axitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Axitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Axitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Axitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-cabozantinib-modafinil', 'modafinil', 'Modafinil', 'cabozantinib', 'Cabozantinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Cabozantinib is a CYP3A4 substrate',
    'Decreased Cabozantinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Cabozantinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Cabozantinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Cabozantinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-ibrutinib-modafinil', 'modafinil', 'Modafinil', 'ibrutinib', 'Ibrutinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ibrutinib is a CYP3A4 substrate',
    'Decreased Ibrutinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ibrutinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ibrutinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ibrutinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-palbociclib', 'modafinil', 'Modafinil', 'palbociclib', 'Palbociclib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Palbociclib is a CYP3A4 substrate',
    'Decreased Palbociclib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Palbociclib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Palbociclib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Palbociclib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-venetoclax', 'modafinil', 'Modafinil', 'venetoclax', 'Venetoclax',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Venetoclax is a CYP3A4 substrate',
    'Decreased Venetoclax plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Venetoclax efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Venetoclax FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Venetoclax is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-olaparib', 'modafinil', 'Modafinil', 'olaparib', 'Olaparib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Olaparib is a CYP3A4 substrate',
    'Decreased Olaparib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Olaparib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Olaparib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Olaparib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-ruxolitinib', 'modafinil', 'Modafinil', 'ruxolitinib', 'Ruxolitinib',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ruxolitinib is a CYP3A4 substrate',
    'Decreased Ruxolitinib plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ruxolitinib efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ruxolitinib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ruxolitinib is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-docetaxel-modafinil', 'modafinil', 'Modafinil', 'docetaxel', 'Docetaxel',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Docetaxel is a CYP3A4 substrate',
    'Decreased Docetaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Docetaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Docetaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Docetaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-paclitaxel', 'modafinil', 'Modafinil', 'paclitaxel', 'Paclitaxel',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Paclitaxel is a CYP3A4 substrate',
    'Decreased Paclitaxel plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Paclitaxel efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Paclitaxel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Paclitaxel is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-vincristine', 'modafinil', 'Modafinil', 'vincristine', 'Vincristine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Vincristine is a CYP3A4 substrate',
    'Decreased Vincristine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vincristine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Vincristine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Vincristine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-vinblastine', 'modafinil', 'Modafinil', 'vinblastine', 'Vinblastine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Vinblastine is a CYP3A4 substrate',
    'Decreased Vinblastine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vinblastine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Vinblastine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Vinblastine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-etoposide-modafinil', 'modafinil', 'Modafinil', 'etoposide', 'Etoposide',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Etoposide is a CYP3A4 substrate',
    'Decreased Etoposide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Etoposide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Etoposide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Etoposide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-irinotecan-modafinil', 'modafinil', 'Modafinil', 'irinotecan', 'Irinotecan',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Irinotecan is a CYP3A4 substrate',
    'Decreased Irinotecan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Irinotecan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Irinotecan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Irinotecan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-maraviroc-modafinil', 'modafinil', 'Modafinil', 'maraviroc', 'Maraviroc',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Maraviroc is a CYP3A4 substrate',
    'Decreased Maraviroc plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Maraviroc efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Maraviroc FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Maraviroc is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-atazanavir-modafinil', 'modafinil', 'Modafinil', 'atazanavir', 'Atazanavir',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Atazanavir is a CYP3A4 substrate',
    'Decreased Atazanavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Atazanavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Atazanavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Atazanavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-darunavir-modafinil', 'modafinil', 'Modafinil', 'darunavir', 'Darunavir',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Darunavir is a CYP3A4 substrate',
    'Decreased Darunavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Darunavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Darunavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Darunavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lopinavir-modafinil', 'modafinil', 'Modafinil', 'lopinavir', 'Lopinavir',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lopinavir is a CYP3A4 substrate',
    'Decreased Lopinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lopinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lopinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lopinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-saquinavir', 'modafinil', 'Modafinil', 'saquinavir', 'Saquinavir',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Saquinavir is a CYP3A4 substrate',
    'Decreased Saquinavir plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Saquinavir efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Saquinavir FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Saquinavir is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-quetiapine_3a4', 'modafinil', 'Modafinil', 'quetiapine_3a4', 'Quetiapine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Quetiapine is a CYP3A4 substrate',
    'Decreased Quetiapine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quetiapine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Quetiapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Quetiapine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lurasidone_3a4-modafinil', 'modafinil', 'Modafinil', 'lurasidone_3a4', 'Lurasidone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lurasidone is a CYP3A4 substrate',
    'Decreased Lurasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lurasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lurasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lurasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-aripiprazole_3a4-modafinil', 'modafinil', 'Modafinil', 'aripiprazole_3a4', 'Aripiprazole',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Aripiprazole is a CYP3A4 substrate',
    'Decreased Aripiprazole plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Aripiprazole efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Aripiprazole is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-ziprasidone_3a4', 'modafinil', 'Modafinil', 'ziprasidone_3a4', 'Ziprasidone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Ziprasidone is a CYP3A4 substrate',
    'Decreased Ziprasidone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Ziprasidone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Ziprasidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Ziprasidone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-trazodone_3a4', 'modafinil', 'Modafinil', 'trazodone_3a4', 'Trazodone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Trazodone is a CYP3A4 substrate',
    'Decreased Trazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Trazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Trazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Trazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-vilazodone', 'modafinil', 'Modafinil', 'vilazodone', 'Vilazodone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Vilazodone is a CYP3A4 substrate',
    'Decreased Vilazodone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Vilazodone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Vilazodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Vilazodone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-carbamazepine_3a4-modafinil', 'modafinil', 'Modafinil', 'carbamazepine_3a4', 'Carbamazepine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Carbamazepine is a CYP3A4 substrate',
    'Decreased Carbamazepine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Carbamazepine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Carbamazepine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Carbamazepine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-tiagabine', 'modafinil', 'Modafinil', 'tiagabine', 'Tiagabine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Tiagabine is a CYP3A4 substrate',
    'Decreased Tiagabine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tiagabine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Tiagabine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Tiagabine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-zonisamide', 'modafinil', 'Modafinil', 'zonisamide', 'Zonisamide',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Zonisamide is a CYP3A4 substrate',
    'Decreased Zonisamide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zonisamide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Zonisamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Zonisamide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-zolpidem_3a4', 'modafinil', 'Modafinil', 'zolpidem_3a4', 'Zolpidem',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Zolpidem is a CYP3A4 substrate',
    'Decreased Zolpidem plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zolpidem efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Zolpidem FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Zolpidem is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-zaleplon', 'modafinil', 'Modafinil', 'zaleplon', 'Zaleplon',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Zaleplon is a CYP3A4 substrate',
    'Decreased Zaleplon plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Zaleplon efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Zaleplon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Zaleplon is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eszopiclone_3a4-modafinil', 'modafinil', 'Modafinil', 'eszopiclone_3a4', 'Eszopiclone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Eszopiclone is a CYP3A4 substrate',
    'Decreased Eszopiclone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eszopiclone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Eszopiclone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Eszopiclone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-suvorexant', 'modafinil', 'Modafinil', 'suvorexant', 'Suvorexant',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Suvorexant is a CYP3A4 substrate',
    'Decreased Suvorexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Suvorexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Suvorexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Suvorexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-lemborexant-modafinil', 'modafinil', 'Modafinil', 'lemborexant', 'Lemborexant',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Lemborexant is a CYP3A4 substrate',
    'Decreased Lemborexant plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Lemborexant efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Lemborexant FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Lemborexant is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-hydrocortisone-modafinil', 'modafinil', 'Modafinil', 'hydrocortisone', 'Hydrocortisone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Hydrocortisone is a CYP3A4 substrate',
    'Decreased Hydrocortisone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Hydrocortisone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Hydrocortisone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Hydrocortisone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-budesonide-modafinil', 'modafinil', 'Modafinil', 'budesonide', 'Budesonide',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Budesonide is a CYP3A4 substrate',
    'Decreased Budesonide plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Budesonide efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Budesonide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Budesonide is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-methylprednisolone-modafinil', 'modafinil', 'Modafinil', 'methylprednisolone', 'Methylprednisolone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Methylprednisolone is a CYP3A4 substrate',
    'Decreased Methylprednisolone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Methylprednisolone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Methylprednisolone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Methylprednisolone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dexamethasone-modafinil', 'modafinil', 'Modafinil', 'dexamethasone', 'Dexamethasone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Dexamethasone is a CYP3A4 substrate',
    'Decreased Dexamethasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dexamethasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Dexamethasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Dexamethasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-fluticasone-modafinil', 'modafinil', 'Modafinil', 'fluticasone', 'Fluticasone',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Fluticasone is a CYP3A4 substrate',
    'Decreased Fluticasone plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Fluticasone efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Fluticasone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Fluticasone is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-quinidine_3a4', 'modafinil', 'Modafinil', 'quinidine_3a4', 'Quinidine',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Quinidine is a CYP3A4 substrate',
    'Decreased Quinidine plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Quinidine efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Quinidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Quinidine is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-eletriptan-modafinil', 'modafinil', 'Modafinil', 'eletriptan', 'Eletriptan',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Eletriptan is a CYP3A4 substrate',
    'Decreased Eletriptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Eletriptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Eletriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Eletriptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-alfuzosin-modafinil', 'modafinil', 'Modafinil', 'alfuzosin', 'Alfuzosin',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Alfuzosin is a CYP3A4 substrate',
    'Decreased Alfuzosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Alfuzosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Alfuzosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Alfuzosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-tamsulosin', 'modafinil', 'Modafinil', 'tamsulosin', 'Tamsulosin',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Tamsulosin is a CYP3A4 substrate',
    'Decreased Tamsulosin plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tamsulosin efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Tamsulosin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Tamsulosin is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-finasteride-modafinil', 'modafinil', 'Modafinil', 'finasteride', 'Finasteride',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Finasteride is a CYP3A4 substrate',
    'Decreased Finasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Finasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Finasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Finasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-dutasteride-modafinil', 'modafinil', 'Modafinil', 'dutasteride', 'Dutasteride',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Dutasteride is a CYP3A4 substrate',
    'Decreased Dutasteride plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Dutasteride efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Dutasteride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Dutasteride is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-modafinil-tolvaptan', 'modafinil', 'Modafinil', 'tolvaptan', 'Tolvaptan',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Tolvaptan is a CYP3A4 substrate',
    'Decreased Tolvaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Tolvaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Tolvaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Tolvaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp3a4_interaction-conivaptan-modafinil', 'modafinil', 'Modafinil', 'conivaptan', 'Conivaptan',
    'cyp3a4_interaction', 'moderate', 'probable',
    'Modafinil induces CYP3A4; Conivaptan is a CYP3A4 substrate',
    'Decreased Conivaptan plasma levels due to induced CYP3A4 metabolism; potential for reduced efficacy',
    'Monitor Conivaptan efficacy; may need dose increase or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Modafinil and Conivaptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Modafinil induces CYP3A4; Conivaptan is a CYP3A4 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-codeine-fluoxetine', 'fluoxetine', 'Fluoxetine', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-tramadol', 'fluoxetine', 'Fluoxetine', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-hydrocodone', 'fluoxetine', 'Fluoxetine', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-metoprolol', 'fluoxetine', 'Fluoxetine', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-fluoxetine', 'fluoxetine', 'Fluoxetine', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-propranolol', 'fluoxetine', 'Fluoxetine', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-timolol', 'fluoxetine', 'Fluoxetine', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-flecainide-fluoxetine', 'fluoxetine', 'Fluoxetine', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-propafenone', 'fluoxetine', 'Fluoxetine', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-tamoxifen', 'fluoxetine', 'Fluoxetine', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-fluoxetine', 'fluoxetine', 'Fluoxetine', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dextromethorphan-fluoxetine', 'fluoxetine', 'Fluoxetine', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-perphenazine', 'fluoxetine', 'Fluoxetine', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-thioridazine_cyp', 'fluoxetine', 'Fluoxetine', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-nebivolol', 'fluoxetine', 'Fluoxetine', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-mexiletine', 'fluoxetine', 'Fluoxetine', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-encainide-fluoxetine', 'fluoxetine', 'Fluoxetine', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-debrisoquine-fluoxetine', 'fluoxetine', 'Fluoxetine', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-fluoxetine', 'fluoxetine', 'Fluoxetine', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-iloperidone_cyp', 'fluoxetine', 'Fluoxetine', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-vortioxetine', 'fluoxetine', 'Fluoxetine', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-fluoxetine', 'fluoxetine', 'Fluoxetine', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-nortriptyline_cyp', 'fluoxetine', 'Fluoxetine', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-imipramine_cyp', 'fluoxetine', 'Fluoxetine', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-desipramine_cyp-fluoxetine', 'fluoxetine', 'Fluoxetine', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-clomipramine_cyp-fluoxetine', 'fluoxetine', 'Fluoxetine', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-venlafaxine_cyp', 'fluoxetine', 'Fluoxetine', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-ondansetron_cyp', 'fluoxetine', 'Fluoxetine', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-fluoxetine-oxycodone_cyp', 'fluoxetine', 'Fluoxetine', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dihydrocodeine-fluoxetine', 'fluoxetine', 'Fluoxetine', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'major', 'established',
    'Fluoxetine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-codeine-paroxetine', 'paroxetine', 'Paroxetine', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-tramadol', 'paroxetine', 'Paroxetine', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-hydrocodone-paroxetine', 'paroxetine', 'Paroxetine', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-metoprolol-paroxetine', 'paroxetine', 'Paroxetine', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-paroxetine', 'paroxetine', 'Paroxetine', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-propranolol', 'paroxetine', 'Paroxetine', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-timolol', 'paroxetine', 'Paroxetine', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-flecainide-paroxetine', 'paroxetine', 'Paroxetine', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-propafenone', 'paroxetine', 'Paroxetine', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-tamoxifen', 'paroxetine', 'Paroxetine', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-paroxetine', 'paroxetine', 'Paroxetine', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dextromethorphan-paroxetine', 'paroxetine', 'Paroxetine', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-perphenazine', 'paroxetine', 'Paroxetine', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-thioridazine_cyp', 'paroxetine', 'Paroxetine', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nebivolol-paroxetine', 'paroxetine', 'Paroxetine', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-mexiletine-paroxetine', 'paroxetine', 'Paroxetine', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-encainide-paroxetine', 'paroxetine', 'Paroxetine', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-debrisoquine-paroxetine', 'paroxetine', 'Paroxetine', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-iloperidone_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-vortioxetine', 'paroxetine', 'Paroxetine', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nortriptyline_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-imipramine_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-desipramine_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-clomipramine_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-paroxetine-venlafaxine_cyp', 'paroxetine', 'Paroxetine', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-ondansetron_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-oxycodone_cyp-paroxetine', 'paroxetine', 'Paroxetine', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dihydrocodeine-paroxetine', 'paroxetine', 'Paroxetine', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'major', 'established',
    'Paroxetine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Paroxetine and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Paroxetine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-codeine', 'bupropion', 'Bupropion', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-tramadol', 'bupropion', 'Bupropion', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-hydrocodone', 'bupropion', 'Bupropion', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-metoprolol', 'bupropion', 'Bupropion', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-carvedilol', 'bupropion', 'Bupropion', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-propranolol', 'bupropion', 'Bupropion', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-timolol', 'bupropion', 'Bupropion', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-flecainide', 'bupropion', 'Bupropion', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-propafenone', 'bupropion', 'Bupropion', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-tamoxifen', 'bupropion', 'Bupropion', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-bupropion', 'bupropion', 'Bupropion', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-dextromethorphan', 'bupropion', 'Bupropion', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-perphenazine', 'bupropion', 'Bupropion', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-thioridazine_cyp', 'bupropion', 'Bupropion', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-nebivolol', 'bupropion', 'Bupropion', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-mexiletine', 'bupropion', 'Bupropion', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-encainide', 'bupropion', 'Bupropion', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-debrisoquine', 'bupropion', 'Bupropion', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-bupropion', 'bupropion', 'Bupropion', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-iloperidone_cyp', 'bupropion', 'Bupropion', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-vortioxetine', 'bupropion', 'Bupropion', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-bupropion', 'bupropion', 'Bupropion', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-nortriptyline_cyp', 'bupropion', 'Bupropion', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-imipramine_cyp', 'bupropion', 'Bupropion', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-desipramine_cyp', 'bupropion', 'Bupropion', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-clomipramine_cyp', 'bupropion', 'Bupropion', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-venlafaxine_cyp', 'bupropion', 'Bupropion', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-ondansetron_cyp', 'bupropion', 'Bupropion', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-oxycodone_cyp', 'bupropion', 'Bupropion', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-bupropion-dihydrocodeine', 'bupropion', 'Bupropion', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Bupropion is a moderate CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Bupropion and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Bupropion is a moderate CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-codeine-duloxetine', 'duloxetine', 'Duloxetine', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-tramadol', 'duloxetine', 'Duloxetine', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-hydrocodone', 'duloxetine', 'Duloxetine', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-metoprolol', 'duloxetine', 'Duloxetine', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-duloxetine', 'duloxetine', 'Duloxetine', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-propranolol', 'duloxetine', 'Duloxetine', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-timolol', 'duloxetine', 'Duloxetine', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-flecainide', 'duloxetine', 'Duloxetine', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-propafenone', 'duloxetine', 'Duloxetine', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-tamoxifen', 'duloxetine', 'Duloxetine', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-duloxetine', 'duloxetine', 'Duloxetine', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dextromethorphan-duloxetine', 'duloxetine', 'Duloxetine', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-perphenazine', 'duloxetine', 'Duloxetine', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-thioridazine_cyp', 'duloxetine', 'Duloxetine', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-nebivolol', 'duloxetine', 'Duloxetine', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-mexiletine', 'duloxetine', 'Duloxetine', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-encainide', 'duloxetine', 'Duloxetine', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-debrisoquine-duloxetine', 'duloxetine', 'Duloxetine', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-duloxetine', 'duloxetine', 'Duloxetine', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-iloperidone_cyp', 'duloxetine', 'Duloxetine', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-vortioxetine', 'duloxetine', 'Duloxetine', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-duloxetine', 'duloxetine', 'Duloxetine', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-nortriptyline_cyp', 'duloxetine', 'Duloxetine', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-imipramine_cyp', 'duloxetine', 'Duloxetine', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-desipramine_cyp-duloxetine', 'duloxetine', 'Duloxetine', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-clomipramine_cyp-duloxetine', 'duloxetine', 'Duloxetine', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-venlafaxine_cyp', 'duloxetine', 'Duloxetine', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-ondansetron_cyp', 'duloxetine', 'Duloxetine', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-duloxetine-oxycodone_cyp', 'duloxetine', 'Duloxetine', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dihydrocodeine-duloxetine', 'duloxetine', 'Duloxetine', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'moderate', 'established',
    'Duloxetine is a moderate CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Duloxetine and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Duloxetine is a moderate CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-codeine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-tramadol', 'quinidine_cyp', 'Quinidine', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-hydrocodone-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-metoprolol-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-propranolol-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-timolol', 'quinidine_cyp', 'Quinidine', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-flecainide-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-propafenone-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-tamoxifen', 'quinidine_cyp', 'Quinidine', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dextromethorphan-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-perphenazine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-thioridazine_cyp', 'quinidine_cyp', 'Quinidine', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nebivolol-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-mexiletine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-encainide-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-debrisoquine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-iloperidone_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-vortioxetine', 'quinidine_cyp', 'Quinidine', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nortriptyline_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-imipramine_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-desipramine_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-clomipramine_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-quinidine_cyp-venlafaxine_cyp', 'quinidine_cyp', 'Quinidine', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-ondansetron_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-oxycodone_cyp-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dihydrocodeine-quinidine_cyp', 'quinidine_cyp', 'Quinidine', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'major', 'established',
    'Quinidine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Quinidine and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Quinidine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-codeine-terbinafine', 'terbinafine', 'Terbinafine', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-terbinafine-tramadol', 'terbinafine', 'Terbinafine', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-hydrocodone-terbinafine', 'terbinafine', 'Terbinafine', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-metoprolol-terbinafine', 'terbinafine', 'Terbinafine', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-terbinafine', 'terbinafine', 'Terbinafine', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-propranolol-terbinafine', 'terbinafine', 'Terbinafine', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-terbinafine-timolol', 'terbinafine', 'Terbinafine', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-flecainide-terbinafine', 'terbinafine', 'Terbinafine', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-propafenone-terbinafine', 'terbinafine', 'Terbinafine', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-tamoxifen-terbinafine', 'terbinafine', 'Terbinafine', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-terbinafine', 'terbinafine', 'Terbinafine', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dextromethorphan-terbinafine', 'terbinafine', 'Terbinafine', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-perphenazine-terbinafine', 'terbinafine', 'Terbinafine', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-terbinafine-thioridazine_cyp', 'terbinafine', 'Terbinafine', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nebivolol-terbinafine', 'terbinafine', 'Terbinafine', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-mexiletine-terbinafine', 'terbinafine', 'Terbinafine', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-encainide-terbinafine', 'terbinafine', 'Terbinafine', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-debrisoquine-terbinafine', 'terbinafine', 'Terbinafine', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-iloperidone_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-terbinafine-vortioxetine', 'terbinafine', 'Terbinafine', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-nortriptyline_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-imipramine_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-desipramine_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-clomipramine_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-terbinafine-venlafaxine_cyp', 'terbinafine', 'Terbinafine', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-ondansetron_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-oxycodone_cyp-terbinafine', 'terbinafine', 'Terbinafine', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-dihydrocodeine-terbinafine', 'terbinafine', 'Terbinafine', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'major', 'established',
    'Terbinafine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Terbinafine and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Terbinafine is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-codeine', 'cinacalcet', 'Cinacalcet', 'codeine', 'Codeine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate',
    'Increased Codeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Codeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Codeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Codeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-tramadol', 'cinacalcet', 'Cinacalcet', 'tramadol', 'Tramadol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate',
    'Increased Tramadol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tramadol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Tramadol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Tramadol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-hydrocodone', 'cinacalcet', 'Cinacalcet', 'hydrocodone', 'Hydrocodone',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate',
    'Increased Hydrocodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Hydrocodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Hydrocodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Hydrocodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-metoprolol', 'cinacalcet', 'Cinacalcet', 'metoprolol', 'Metoprolol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate',
    'Increased Metoprolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Metoprolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Metoprolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Metoprolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-carvedilol-cinacalcet', 'cinacalcet', 'Cinacalcet', 'carvedilol', 'Carvedilol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate',
    'Increased Carvedilol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Carvedilol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Carvedilol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Carvedilol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-propranolol', 'cinacalcet', 'Cinacalcet', 'propranolol', 'Propranolol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate',
    'Increased Propranolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propranolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Propranolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Propranolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-timolol', 'cinacalcet', 'Cinacalcet', 'timolol', 'Timolol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate',
    'Increased Timolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Timolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Timolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Timolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-flecainide', 'cinacalcet', 'Cinacalcet', 'flecainide', 'Flecainide',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate',
    'Increased Flecainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Flecainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Flecainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Flecainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-propafenone', 'cinacalcet', 'Cinacalcet', 'propafenone', 'Propafenone',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate',
    'Increased Propafenone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Propafenone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Propafenone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Propafenone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-tamoxifen', 'cinacalcet', 'Cinacalcet', 'tamoxifen', 'Tamoxifen',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate',
    'Increased Tamoxifen plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Tamoxifen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Tamoxifen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Tamoxifen is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-atomoxetine-cinacalcet', 'cinacalcet', 'Cinacalcet', 'atomoxetine', 'Atomoxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate',
    'Increased Atomoxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Atomoxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Atomoxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Atomoxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-dextromethorphan', 'cinacalcet', 'Cinacalcet', 'dextromethorphan', 'Dextromethorphan',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate',
    'Increased Dextromethorphan plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dextromethorphan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Dextromethorphan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Dextromethorphan is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-perphenazine', 'cinacalcet', 'Cinacalcet', 'perphenazine', 'Perphenazine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate',
    'Increased Perphenazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Perphenazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Perphenazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Perphenazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-thioridazine_cyp', 'cinacalcet', 'Cinacalcet', 'thioridazine_cyp', 'Thioridazine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate',
    'Increased Thioridazine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Thioridazine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Thioridazine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Thioridazine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-nebivolol', 'cinacalcet', 'Cinacalcet', 'nebivolol', 'Nebivolol',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate',
    'Increased Nebivolol plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nebivolol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Nebivolol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Nebivolol is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-mexiletine', 'cinacalcet', 'Cinacalcet', 'mexiletine', 'Mexiletine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate',
    'Increased Mexiletine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Mexiletine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Mexiletine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Mexiletine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-encainide', 'cinacalcet', 'Cinacalcet', 'encainide', 'Encainide',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate',
    'Increased Encainide plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Encainide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Encainide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Encainide is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-debrisoquine', 'cinacalcet', 'Cinacalcet', 'debrisoquine', 'Debrisoquine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate',
    'Increased Debrisoquine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Debrisoquine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Debrisoquine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Debrisoquine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-aripiprazole_cyp-cinacalcet', 'cinacalcet', 'Cinacalcet', 'aripiprazole_cyp', 'Aripiprazole',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate',
    'Increased Aripiprazole plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Aripiprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Aripiprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Aripiprazole is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-iloperidone_cyp', 'cinacalcet', 'Cinacalcet', 'iloperidone_cyp', 'Iloperidone',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate',
    'Increased Iloperidone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Iloperidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Iloperidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Iloperidone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-vortioxetine', 'cinacalcet', 'Cinacalcet', 'vortioxetine', 'Vortioxetine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate',
    'Increased Vortioxetine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Vortioxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Vortioxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Vortioxetine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-amitriptyline_cyp-cinacalcet', 'cinacalcet', 'Cinacalcet', 'amitriptyline_cyp', 'Amitriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Amitriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-nortriptyline_cyp', 'cinacalcet', 'Cinacalcet', 'nortriptyline_cyp', 'Nortriptyline',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate',
    'Increased Nortriptyline plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Nortriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Nortriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Nortriptyline is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-imipramine_cyp', 'cinacalcet', 'Cinacalcet', 'imipramine_cyp', 'Imipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Imipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-desipramine_cyp', 'cinacalcet', 'Cinacalcet', 'desipramine_cyp', 'Desipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate',
    'Increased Desipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Desipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Desipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Desipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-clomipramine_cyp', 'cinacalcet', 'Cinacalcet', 'clomipramine_cyp', 'Clomipramine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Clomipramine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-venlafaxine_cyp', 'cinacalcet', 'Cinacalcet', 'venlafaxine_cyp', 'Venlafaxine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate',
    'Increased Venlafaxine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Venlafaxine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Venlafaxine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Venlafaxine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-ondansetron_cyp', 'cinacalcet', 'Cinacalcet', 'ondansetron_cyp', 'Ondansetron',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate',
    'Increased Ondansetron plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Ondansetron toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Ondansetron FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Ondansetron is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-oxycodone_cyp', 'cinacalcet', 'Cinacalcet', 'oxycodone_cyp', 'Oxycodone',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate',
    'Increased Oxycodone plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Oxycodone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Oxycodone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Oxycodone is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2d6_interaction-cinacalcet-dihydrocodeine', 'cinacalcet', 'Cinacalcet', 'dihydrocodeine', 'Dihydrocodeine',
    'cyp2d6_interaction', 'major', 'established',
    'Cinacalcet is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate',
    'Increased Dihydrocodeine plasma levels due to reduced CYP2D6 metabolism; potential for toxicity',
    'Monitor for Dihydrocodeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Cinacalcet and Dihydrocodeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cinacalcet is a strong CYP2D6 inhibitor; Dihydrocodeine is a CYP2D6 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-warfarin_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-phenytoin_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-tolbutamide', 'fluconazole_cyp2c9', 'Fluconazole', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-glipizide', 'fluconazole_cyp2c9', 'Fluconazole', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-glyburide', 'fluconazole_cyp2c9', 'Fluconazole', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-glimepiride', 'fluconazole_cyp2c9', 'Fluconazole', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-losartan_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-irbesartan', 'fluconazole_cyp2c9', 'Fluconazole', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-ibuprofen_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-naproxen_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-fluconazole_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-fluconazole_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-meloxicam_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-piroxicam', 'fluconazole_cyp2c9', 'Fluconazole', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-flurbiprofen', 'fluconazole_cyp2c9', 'Fluconazole', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-tenoxicam', 'fluconazole_cyp2c9', 'Fluconazole', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-lornoxicam', 'fluconazole_cyp2c9', 'Fluconazole', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-torsemide', 'fluconazole_cyp2c9', 'Fluconazole', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-fluvastatin', 'fluconazole_cyp2c9', 'Fluconazole', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-rosiglitazone', 'fluconazole_cyp2c9', 'Fluconazole', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-pioglitazone', 'fluconazole_cyp2c9', 'Fluconazole', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-fluconazole_cyp2c9', 'fluconazole_cyp2c9', 'Fluconazole', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluconazole_cyp2c9-siponimod', 'fluconazole_cyp2c9', 'Fluconazole', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-warfarin_cyp2c9', 'miconazole', 'Miconazole', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-phenytoin_cyp2c9', 'miconazole', 'Miconazole', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-tolbutamide', 'miconazole', 'Miconazole', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glipizide-miconazole', 'miconazole', 'Miconazole', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glyburide-miconazole', 'miconazole', 'Miconazole', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glimepiride-miconazole', 'miconazole', 'Miconazole', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-losartan_cyp2c9-miconazole', 'miconazole', 'Miconazole', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-irbesartan-miconazole', 'miconazole', 'Miconazole', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-ibuprofen_cyp2c9-miconazole', 'miconazole', 'Miconazole', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-naproxen_cyp2c9', 'miconazole', 'Miconazole', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-miconazole', 'miconazole', 'Miconazole', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-miconazole', 'miconazole', 'Miconazole', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-meloxicam_cyp2c9-miconazole', 'miconazole', 'Miconazole', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-piroxicam', 'miconazole', 'Miconazole', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-miconazole', 'miconazole', 'Miconazole', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-tenoxicam', 'miconazole', 'Miconazole', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-lornoxicam-miconazole', 'miconazole', 'Miconazole', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-torsemide', 'miconazole', 'Miconazole', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-miconazole', 'miconazole', 'Miconazole', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-rosiglitazone', 'miconazole', 'Miconazole', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-pioglitazone', 'miconazole', 'Miconazole', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-miconazole', 'miconazole', 'Miconazole', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-miconazole-siponimod', 'miconazole', 'Miconazole', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'major', 'established',
    'Miconazole is a strong CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Miconazole and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Miconazole is a strong CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-warfarin_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-phenytoin_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-tolbutamide', 'amiodarone_cyp2c9', 'Amiodarone', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-glipizide', 'amiodarone_cyp2c9', 'Amiodarone', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-glyburide', 'amiodarone_cyp2c9', 'Amiodarone', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-glimepiride', 'amiodarone_cyp2c9', 'Amiodarone', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-losartan_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-irbesartan', 'amiodarone_cyp2c9', 'Amiodarone', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-ibuprofen_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-naproxen_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-diclofenac_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-celecoxib_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-meloxicam_cyp2c9', 'amiodarone_cyp2c9', 'Amiodarone', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-piroxicam', 'amiodarone_cyp2c9', 'Amiodarone', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-flurbiprofen', 'amiodarone_cyp2c9', 'Amiodarone', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-tenoxicam', 'amiodarone_cyp2c9', 'Amiodarone', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-lornoxicam', 'amiodarone_cyp2c9', 'Amiodarone', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-torsemide', 'amiodarone_cyp2c9', 'Amiodarone', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-fluvastatin', 'amiodarone_cyp2c9', 'Amiodarone', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-rosiglitazone', 'amiodarone_cyp2c9', 'Amiodarone', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-pioglitazone', 'amiodarone_cyp2c9', 'Amiodarone', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-bosentan', 'amiodarone_cyp2c9', 'Amiodarone', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-amiodarone_cyp2c9-siponimod', 'amiodarone_cyp2c9', 'Amiodarone', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'moderate', 'established',
    'Amiodarone is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Amiodarone and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Amiodarone is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-warfarin_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-phenytoin_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-tolbutamide', 'fluvoxamine', 'Fluvoxamine', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-glipizide', 'fluvoxamine', 'Fluvoxamine', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-glyburide', 'fluvoxamine', 'Fluvoxamine', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-glimepiride', 'fluvoxamine', 'Fluvoxamine', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-losartan_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-irbesartan', 'fluvoxamine', 'Fluvoxamine', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-ibuprofen_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-naproxen_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-meloxicam_cyp2c9', 'fluvoxamine', 'Fluvoxamine', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-piroxicam', 'fluvoxamine', 'Fluvoxamine', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-tenoxicam', 'fluvoxamine', 'Fluvoxamine', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-lornoxicam', 'fluvoxamine', 'Fluvoxamine', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-torsemide', 'fluvoxamine', 'Fluvoxamine', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-rosiglitazone', 'fluvoxamine', 'Fluvoxamine', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-pioglitazone', 'fluvoxamine', 'Fluvoxamine', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvoxamine-siponimod', 'fluvoxamine', 'Fluvoxamine', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'moderate', 'established',
    'Fluvoxamine is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-warfarin_cyp2c9', 'metronidazole_cyp', 'Metronidazole', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-phenytoin_cyp2c9', 'metronidazole_cyp', 'Metronidazole', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-tolbutamide', 'metronidazole_cyp', 'Metronidazole', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glipizide-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glyburide-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glimepiride-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-losartan_cyp2c9-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-irbesartan-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-ibuprofen_cyp2c9-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-naproxen_cyp2c9', 'metronidazole_cyp', 'Metronidazole', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-meloxicam_cyp2c9-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-piroxicam', 'metronidazole_cyp', 'Metronidazole', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-tenoxicam', 'metronidazole_cyp', 'Metronidazole', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-lornoxicam-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-torsemide', 'metronidazole_cyp', 'Metronidazole', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-rosiglitazone', 'metronidazole_cyp', 'Metronidazole', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-pioglitazone', 'metronidazole_cyp', 'Metronidazole', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-metronidazole_cyp', 'metronidazole_cyp', 'Metronidazole', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-metronidazole_cyp-siponimod', 'metronidazole_cyp', 'Metronidazole', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'moderate', 'established',
    'Metronidazole is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Metronidazole and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Metronidazole is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-trimethoprim_cyp-warfarin_cyp2c9', 'trimethoprim_cyp', 'Trimethoprim', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-phenytoin_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-tolbutamide-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glipizide-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glyburide-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glimepiride-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-losartan_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-irbesartan-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-ibuprofen_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-naproxen_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-meloxicam_cyp2c9-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-piroxicam-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-tenoxicam-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-lornoxicam-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-torsemide-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-rosiglitazone-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-pioglitazone-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-siponimod-trimethoprim_cyp', 'trimethoprim_cyp', 'Trimethoprim', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'minor', 'probable',
    'Trimethoprim is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Trimethoprim and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Trimethoprim is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfamethoxazole_cyp-warfarin_cyp2c9', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-phenytoin_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfamethoxazole_cyp-tolbutamide', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glipizide-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glyburide-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glimepiride-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-losartan_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-irbesartan-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-ibuprofen_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-naproxen_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-meloxicam_cyp2c9-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-piroxicam-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfamethoxazole_cyp-tenoxicam', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-lornoxicam-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfamethoxazole_cyp-torsemide', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-rosiglitazone-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-pioglitazone-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-siponimod-sulfamethoxazole_cyp', 'sulfamethoxazole_cyp', 'Sulfamethoxazole', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'minor', 'probable',
    'Sulfamethoxazole is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Sulfamethoxazole and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfamethoxazole is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-warfarin_cyp2c9', 'fenofibrate', 'Fenofibrate', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-phenytoin_cyp2c9', 'fenofibrate', 'Fenofibrate', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-tolbutamide', 'fenofibrate', 'Fenofibrate', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-glipizide', 'fenofibrate', 'Fenofibrate', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-glyburide', 'fenofibrate', 'Fenofibrate', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-glimepiride', 'fenofibrate', 'Fenofibrate', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-losartan_cyp2c9', 'fenofibrate', 'Fenofibrate', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-irbesartan', 'fenofibrate', 'Fenofibrate', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-ibuprofen_cyp2c9', 'fenofibrate', 'Fenofibrate', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-naproxen_cyp2c9', 'fenofibrate', 'Fenofibrate', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-fenofibrate', 'fenofibrate', 'Fenofibrate', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-fenofibrate', 'fenofibrate', 'Fenofibrate', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-meloxicam_cyp2c9', 'fenofibrate', 'Fenofibrate', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-piroxicam', 'fenofibrate', 'Fenofibrate', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-flurbiprofen', 'fenofibrate', 'Fenofibrate', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-tenoxicam', 'fenofibrate', 'Fenofibrate', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-lornoxicam', 'fenofibrate', 'Fenofibrate', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-torsemide', 'fenofibrate', 'Fenofibrate', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-fluvastatin', 'fenofibrate', 'Fenofibrate', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-rosiglitazone', 'fenofibrate', 'Fenofibrate', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-pioglitazone', 'fenofibrate', 'Fenofibrate', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-fenofibrate', 'fenofibrate', 'Fenofibrate', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fenofibrate-siponimod', 'fenofibrate', 'Fenofibrate', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fenofibrate is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fenofibrate and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fenofibrate is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfinpyrazone-warfarin_cyp2c9', 'sulfinpyrazone', 'Sulfinpyrazone', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-phenytoin_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfinpyrazone-tolbutamide', 'sulfinpyrazone', 'Sulfinpyrazone', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glipizide-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glyburide-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-glimepiride-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-losartan_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-irbesartan-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-ibuprofen_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-naproxen_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-meloxicam_cyp2c9-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-piroxicam-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-flurbiprofen-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfinpyrazone-tenoxicam', 'sulfinpyrazone', 'Sulfinpyrazone', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-lornoxicam-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-sulfinpyrazone-torsemide', 'sulfinpyrazone', 'Sulfinpyrazone', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluvastatin-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-rosiglitazone-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-pioglitazone-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-siponimod-sulfinpyrazone', 'sulfinpyrazone', 'Sulfinpyrazone', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'moderate', 'established',
    'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Sulfinpyrazone and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Sulfinpyrazone is a moderate CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-warfarin_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'warfarin_cyp2c9', 'Warfarin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate',
    'Increased Warfarin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Warfarin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Warfarin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Warfarin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-phenytoin_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'phenytoin_cyp2c9', 'Phenytoin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate',
    'Increased Phenytoin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Phenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Phenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Phenytoin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-tolbutamide', 'fluoxetine_cyp2c9', 'Fluoxetine', 'tolbutamide', 'Tolbutamide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate',
    'Increased Tolbutamide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tolbutamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Tolbutamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Tolbutamide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-glipizide', 'fluoxetine_cyp2c9', 'Fluoxetine', 'glipizide', 'Glipizide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate',
    'Increased Glipizide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glipizide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Glipizide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Glipizide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-glyburide', 'fluoxetine_cyp2c9', 'Fluoxetine', 'glyburide', 'Glyburide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate',
    'Increased Glyburide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glyburide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Glyburide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Glyburide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-glimepiride', 'fluoxetine_cyp2c9', 'Fluoxetine', 'glimepiride', 'Glimepiride',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate',
    'Increased Glimepiride plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Glimepiride toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Glimepiride FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Glimepiride is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-losartan_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'losartan_cyp2c9', 'Losartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate',
    'Increased Losartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Losartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Losartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Losartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-irbesartan', 'fluoxetine_cyp2c9', 'Fluoxetine', 'irbesartan', 'Irbesartan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate',
    'Increased Irbesartan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Irbesartan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Irbesartan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Irbesartan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-ibuprofen_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'ibuprofen_cyp2c9', 'Ibuprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate',
    'Increased Ibuprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Ibuprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Ibuprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Ibuprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-naproxen_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'naproxen_cyp2c9', 'Naproxen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate',
    'Increased Naproxen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Naproxen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Naproxen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Naproxen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-diclofenac_cyp2c9-fluoxetine_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'diclofenac_cyp2c9', 'Diclofenac',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate',
    'Increased Diclofenac plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Diclofenac toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Diclofenac FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Diclofenac is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-celecoxib_cyp2c9-fluoxetine_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'celecoxib_cyp2c9', 'Celecoxib',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate',
    'Increased Celecoxib plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Celecoxib toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Celecoxib FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Celecoxib is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-meloxicam_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'meloxicam_cyp2c9', 'Meloxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate',
    'Increased Meloxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Meloxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Meloxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Meloxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-piroxicam', 'fluoxetine_cyp2c9', 'Fluoxetine', 'piroxicam', 'Piroxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate',
    'Increased Piroxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Piroxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Piroxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Piroxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-flurbiprofen', 'fluoxetine_cyp2c9', 'Fluoxetine', 'flurbiprofen', 'Flurbiprofen',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate',
    'Increased Flurbiprofen plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Flurbiprofen toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Flurbiprofen FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Flurbiprofen is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-tenoxicam', 'fluoxetine_cyp2c9', 'Fluoxetine', 'tenoxicam', 'Tenoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate',
    'Increased Tenoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Tenoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Tenoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Tenoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-lornoxicam', 'fluoxetine_cyp2c9', 'Fluoxetine', 'lornoxicam', 'Lornoxicam',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate',
    'Increased Lornoxicam plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Lornoxicam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Lornoxicam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Lornoxicam is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-torsemide', 'fluoxetine_cyp2c9', 'Fluoxetine', 'torsemide', 'Torsemide',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate',
    'Increased Torsemide plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Torsemide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Torsemide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Torsemide is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-fluvastatin', 'fluoxetine_cyp2c9', 'Fluoxetine', 'fluvastatin', 'Fluvastatin',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate',
    'Increased Fluvastatin plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Fluvastatin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Fluvastatin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Fluvastatin is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-rosiglitazone', 'fluoxetine_cyp2c9', 'Fluoxetine', 'rosiglitazone', 'Rosiglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate',
    'Increased Rosiglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Rosiglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Rosiglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Rosiglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-pioglitazone', 'fluoxetine_cyp2c9', 'Fluoxetine', 'pioglitazone', 'Pioglitazone',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate',
    'Increased Pioglitazone plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Pioglitazone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Pioglitazone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Pioglitazone is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-bosentan-fluoxetine_cyp2c9', 'fluoxetine_cyp2c9', 'Fluoxetine', 'bosentan', 'Bosentan',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate',
    'Increased Bosentan plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Bosentan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Bosentan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Bosentan is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c9_interaction-fluoxetine_cyp2c9-siponimod', 'fluoxetine_cyp2c9', 'Fluoxetine', 'siponimod', 'Siponimod',
    'cyp2c9_interaction', 'minor', 'probable',
    'Fluoxetine is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate',
    'Increased Siponimod plasma levels due to reduced CYP2C9 metabolism; potential for toxicity',
    'Monitor for Siponimod toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Fluoxetine and Siponimod FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a weak CYP2C9 inhibitor; Siponimod is a CYP2C9 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-sertraline_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-omeprazole_sub', 'omeprazole_cyp2c19', 'Omeprazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-pantoprazole_sub', 'omeprazole_cyp2c19', 'Omeprazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-proguanil', 'omeprazole_cyp2c19', 'Omeprazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-voriconazole_sub', 'omeprazole_cyp2c19', 'Omeprazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_cyp2c19-phenobarbital_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-omeprazole_cyp2c19', 'omeprazole_cyp2c19', 'Omeprazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'moderate', 'established',
    'Omeprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Omeprazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Omeprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-sertraline_cyp2c19', 'esomeprazole', 'Esomeprazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-imipramine_cyp2c19', 'esomeprazole', 'Esomeprazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-esomeprazole', 'esomeprazole', 'Esomeprazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-omeprazole_sub', 'esomeprazole', 'Esomeprazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-lansoprazole_sub', 'esomeprazole', 'Esomeprazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-pantoprazole_sub', 'esomeprazole', 'Esomeprazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-proguanil', 'esomeprazole', 'Esomeprazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-voriconazole_sub', 'esomeprazole', 'Esomeprazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-phenobarbital_cyp2c19', 'esomeprazole', 'Esomeprazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-mephenytoin', 'esomeprazole', 'Esomeprazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-esomeprazole', 'esomeprazole', 'Esomeprazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-esomeprazole', 'esomeprazole', 'Esomeprazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-esomeprazole', 'esomeprazole', 'Esomeprazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-esomeprazole-lacosamide', 'esomeprazole', 'Esomeprazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'moderate', 'established',
    'Esomeprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Esomeprazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Esomeprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-sertraline_cyp2c19', 'lansoprazole', 'Lansoprazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-lansoprazole', 'lansoprazole', 'Lansoprazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-omeprazole_sub', 'lansoprazole', 'Lansoprazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-lansoprazole_sub', 'lansoprazole', 'Lansoprazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-pantoprazole_sub', 'lansoprazole', 'Lansoprazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-proguanil', 'lansoprazole', 'Lansoprazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-voriconazole_sub', 'lansoprazole', 'Lansoprazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-phenobarbital_cyp2c19', 'lansoprazole', 'Lansoprazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole-mephenytoin', 'lansoprazole', 'Lansoprazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-lansoprazole', 'lansoprazole', 'Lansoprazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-lansoprazole', 'lansoprazole', 'Lansoprazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-lansoprazole', 'lansoprazole', 'Lansoprazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-lansoprazole', 'lansoprazole', 'Lansoprazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'moderate', 'established',
    'Lansoprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Lansoprazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Lansoprazole is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole-sertraline_cyp2c19', 'pantoprazole', 'Pantoprazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-pantoprazole', 'pantoprazole', 'Pantoprazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_sub-pantoprazole', 'pantoprazole', 'Pantoprazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-pantoprazole', 'pantoprazole', 'Pantoprazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole-pantoprazole_sub', 'pantoprazole', 'Pantoprazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole-proguanil', 'pantoprazole', 'Pantoprazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole-voriconazole_sub', 'pantoprazole', 'Pantoprazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole-phenobarbital_cyp2c19', 'pantoprazole', 'Pantoprazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-pantoprazole', 'pantoprazole', 'Pantoprazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-pantoprazole', 'pantoprazole', 'Pantoprazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-pantoprazole', 'pantoprazole', 'Pantoprazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-pantoprazole', 'pantoprazole', 'Pantoprazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-pantoprazole', 'pantoprazole', 'Pantoprazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'minor', 'probable',
    'Pantoprazole is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Pantoprazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Pantoprazole is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-rabeprazole-sertraline_cyp2c19', 'rabeprazole', 'Rabeprazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_sub-rabeprazole', 'rabeprazole', 'Rabeprazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-rabeprazole', 'rabeprazole', 'Rabeprazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole_sub-rabeprazole', 'rabeprazole', 'Rabeprazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-proguanil-rabeprazole', 'rabeprazole', 'Rabeprazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-rabeprazole-voriconazole_sub', 'rabeprazole', 'Rabeprazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-phenobarbital_cyp2c19-rabeprazole', 'rabeprazole', 'Rabeprazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-rabeprazole', 'rabeprazole', 'Rabeprazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-rabeprazole', 'rabeprazole', 'Rabeprazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-rabeprazole', 'rabeprazole', 'Rabeprazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-rabeprazole', 'rabeprazole', 'Rabeprazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-rabeprazole', 'rabeprazole', 'Rabeprazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'minor', 'probable',
    'Rabeprazole is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Rabeprazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Rabeprazole is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-sertraline_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-imipramine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-omeprazole_sub', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-lansoprazole_sub', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-pantoprazole_sub', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-proguanil', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-voriconazole_sub', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-phenobarbital_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-mephenytoin', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-fluvoxamine_cyp2c19', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluvoxamine_cyp2c19-lacosamide', 'fluvoxamine_cyp2c19', 'Fluvoxamine', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-sertraline_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-imipramine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-omeprazole_sub', 'fluoxetine_cyp2c19', 'Fluoxetine', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-lansoprazole_sub', 'fluoxetine_cyp2c19', 'Fluoxetine', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-pantoprazole_sub', 'fluoxetine_cyp2c19', 'Fluoxetine', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-proguanil', 'fluoxetine_cyp2c19', 'Fluoxetine', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-voriconazole_sub', 'fluoxetine_cyp2c19', 'Fluoxetine', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-phenobarbital_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-mephenytoin', 'fluoxetine_cyp2c19', 'Fluoxetine', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-fluoxetine_cyp2c19', 'fluoxetine_cyp2c19', 'Fluoxetine', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluoxetine_cyp2c19-lacosamide', 'fluoxetine_cyp2c19', 'Fluoxetine', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'moderate', 'established',
    'Fluoxetine is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluoxetine and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluoxetine is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-sertraline_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-imipramine_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-omeprazole_sub', 'fluconazole_cyp2c19', 'Fluconazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-lansoprazole_sub', 'fluconazole_cyp2c19', 'Fluconazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-pantoprazole_sub', 'fluconazole_cyp2c19', 'Fluconazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-proguanil', 'fluconazole_cyp2c19', 'Fluconazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-voriconazole_sub', 'fluconazole_cyp2c19', 'Fluconazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-phenobarbital_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-mephenytoin', 'fluconazole_cyp2c19', 'Fluconazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-fluconazole_cyp2c19', 'fluconazole_cyp2c19', 'Fluconazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-fluconazole_cyp2c19-lacosamide', 'fluconazole_cyp2c19', 'Fluconazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'major', 'established',
    'Fluconazole is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluconazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluconazole is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-sertraline_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_sub-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole_sub-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-proguanil-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-voriconazole_cyp2c19-voriconazole_sub', 'voriconazole_cyp2c19', 'Voriconazole', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-phenobarbital_cyp2c19-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-voriconazole_cyp2c19', 'voriconazole_cyp2c19', 'Voriconazole', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'major', 'established',
    'Voriconazole is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Voriconazole and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Voriconazole is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-sertraline_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-omeprazole_sub-ticlopidine', 'ticlopidine', 'Ticlopidine', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-ticlopidine', 'ticlopidine', 'Ticlopidine', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-pantoprazole_sub-ticlopidine', 'ticlopidine', 'Ticlopidine', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-proguanil-ticlopidine', 'ticlopidine', 'Ticlopidine', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-ticlopidine-voriconazole_sub', 'ticlopidine', 'Ticlopidine', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-phenobarbital_cyp2c19-ticlopidine', 'ticlopidine', 'Ticlopidine', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-ticlopidine', 'ticlopidine', 'Ticlopidine', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-ticlopidine', 'ticlopidine', 'Ticlopidine', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-ticlopidine', 'ticlopidine', 'Ticlopidine', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-ticlopidine', 'ticlopidine', 'Ticlopidine', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-ticlopidine', 'ticlopidine', 'Ticlopidine', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'major', 'established',
    'Ticlopidine is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a strong CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clopidogrel_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-diazepam_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-citalopram_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-escitalopram_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-sertraline_cyp2c19', 'moclobemide', 'Moclobemide', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-imipramine_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clomipramine_cyp2c19-moclobemide', 'moclobemide', 'Moclobemide', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-omeprazole_sub', 'moclobemide', 'Moclobemide', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lansoprazole_sub-moclobemide', 'moclobemide', 'Moclobemide', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-pantoprazole_sub', 'moclobemide', 'Moclobemide', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-proguanil', 'moclobemide', 'Moclobemide', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-voriconazole_sub', 'moclobemide', 'Moclobemide', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-moclobemide-phenobarbital_cyp2c19', 'moclobemide', 'Moclobemide', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-mephenytoin-moclobemide', 'moclobemide', 'Moclobemide', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-moclobemide', 'moclobemide', 'Moclobemide', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-moclobemide', 'moclobemide', 'Moclobemide', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-clobazam-moclobemide', 'moclobemide', 'Moclobemide', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-lacosamide-moclobemide', 'moclobemide', 'Moclobemide', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'moderate', 'established',
    'Moclobemide is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Moclobemide and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Moclobemide is a moderate CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-clopidogrel_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'clopidogrel_cyp2c19', 'Clopidogrel',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate',
    'Increased Clopidogrel plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clopidogrel toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Clopidogrel FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Clopidogrel is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-diazepam_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'diazepam_cyp2c19', 'Diazepam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate',
    'Increased Diazepam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Diazepam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Diazepam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Diazepam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-citalopram_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'citalopram_cyp2c19', 'Citalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate',
    'Increased Citalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Citalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Citalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Citalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-escitalopram_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'escitalopram_cyp2c19', 'Escitalopram',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate',
    'Increased Escitalopram plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Escitalopram toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Escitalopram FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Escitalopram is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-sertraline_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'sertraline_cyp2c19', 'Sertraline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate',
    'Increased Sertraline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Sertraline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Sertraline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Sertraline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-amitriptyline_cyp2c19-cimetidine_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'amitriptyline_cyp2c19', 'Amitriptyline',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate',
    'Increased Amitriptyline plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Amitriptyline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Amitriptyline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Amitriptyline is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-imipramine_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'imipramine_cyp2c19', 'Imipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate',
    'Increased Imipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Imipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Imipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Imipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-clomipramine_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'clomipramine_cyp2c19', 'Clomipramine',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate',
    'Increased Clomipramine plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clomipramine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Clomipramine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Clomipramine is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-omeprazole_sub', 'cimetidine_cyp2c19', 'Cimetidine', 'omeprazole_sub', 'Omeprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate',
    'Increased Omeprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Omeprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Omeprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Omeprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-lansoprazole_sub', 'cimetidine_cyp2c19', 'Cimetidine', 'lansoprazole_sub', 'Lansoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate',
    'Increased Lansoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lansoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lansoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Lansoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-pantoprazole_sub', 'cimetidine_cyp2c19', 'Cimetidine', 'pantoprazole_sub', 'Pantoprazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate',
    'Increased Pantoprazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Pantoprazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Pantoprazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Pantoprazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-proguanil', 'cimetidine_cyp2c19', 'Cimetidine', 'proguanil', 'Proguanil',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate',
    'Increased Proguanil plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Proguanil toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Proguanil FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Proguanil is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-voriconazole_sub', 'cimetidine_cyp2c19', 'Cimetidine', 'voriconazole_sub', 'Voriconazole',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate',
    'Increased Voriconazole plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Voriconazole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Voriconazole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Voriconazole is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-phenobarbital_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'phenobarbital_cyp2c19', 'Phenobarbital',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate',
    'Increased Phenobarbital plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Phenobarbital toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Phenobarbital FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Phenobarbital is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-mephenytoin', 'cimetidine_cyp2c19', 'Cimetidine', 'mephenytoin', 'Mephenytoin',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate',
    'Increased Mephenytoin plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Mephenytoin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Mephenytoin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Mephenytoin is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-carisoprodol-cimetidine_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'carisoprodol', 'Carisoprodol',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate',
    'Increased Carisoprodol plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Carisoprodol toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Carisoprodol FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Carisoprodol is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-brivaracetam-cimetidine_cyp2c19', 'cimetidine_cyp2c19', 'Cimetidine', 'brivaracetam', 'Brivaracetam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate',
    'Increased Brivaracetam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Brivaracetam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Brivaracetam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Brivaracetam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-clobazam', 'cimetidine_cyp2c19', 'Cimetidine', 'clobazam', 'Clobazam',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate',
    'Increased Clobazam plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Clobazam toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Clobazam FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Clobazam is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp2c19_interaction-cimetidine_cyp2c19-lacosamide', 'cimetidine_cyp2c19', 'Cimetidine', 'lacosamide', 'Lacosamide',
    'cyp2c19_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate',
    'Increased Lacosamide plasma levels due to reduced CYP2C19 metabolism; potential for toxicity',
    'Monitor for Lacosamide toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Lacosamide FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP2C19 inhibitor; Lacosamide is a CYP2C19 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-theophylline', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-fluvoxamine_cyp1a2', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-clozapine_cyp1a2-fluvoxamine_cyp1a2', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-olanzapine_cyp1a2', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-duloxetine_cyp1a2-fluvoxamine_cyp1a2', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-ropinirole', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-ramelteon', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-tizanidine', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-frovatriptan', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-zolmitriptan', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-melatonin', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-tasimelteon', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-fluvoxamine_cyp1a2-pirfenidone', 'fluvoxamine_cyp1a2', 'Fluvoxamine', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'major', 'established',
    'Fluvoxamine is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Fluvoxamine and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Fluvoxamine is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-theophylline', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-ciprofloxacin_cyp1a2', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-clozapine_cyp1a2', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-olanzapine_cyp1a2', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-duloxetine_cyp1a2', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-ropinirole', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-ramelteon', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-tizanidine', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-frovatriptan', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-zolmitriptan', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-melatonin', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-tasimelteon', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ciprofloxacin_cyp1a2-pirfenidone', 'ciprofloxacin_cyp1a2', 'Ciprofloxacin', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'major', 'established',
    'Ciprofloxacin is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ciprofloxacin and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ciprofloxacin is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-theophylline', 'enoxacin', 'Enoxacin', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-enoxacin', 'enoxacin', 'Enoxacin', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-clozapine_cyp1a2-enoxacin', 'enoxacin', 'Enoxacin', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-olanzapine_cyp1a2', 'enoxacin', 'Enoxacin', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-duloxetine_cyp1a2-enoxacin', 'enoxacin', 'Enoxacin', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-ropinirole', 'enoxacin', 'Enoxacin', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-ramelteon', 'enoxacin', 'Enoxacin', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-tizanidine', 'enoxacin', 'Enoxacin', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-frovatriptan', 'enoxacin', 'Enoxacin', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-zolmitriptan', 'enoxacin', 'Enoxacin', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-melatonin', 'enoxacin', 'Enoxacin', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-tasimelteon', 'enoxacin', 'Enoxacin', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-enoxacin-pirfenidone', 'enoxacin', 'Enoxacin', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'major', 'established',
    'Enoxacin is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Enoxacin and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Enoxacin is a strong CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-theophylline', 'mexiletine_cyp1a2', 'Mexiletine', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-mexiletine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-clozapine_cyp1a2-mexiletine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-olanzapine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-duloxetine_cyp1a2-mexiletine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-ropinirole', 'mexiletine_cyp1a2', 'Mexiletine', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-ramelteon', 'mexiletine_cyp1a2', 'Mexiletine', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-tizanidine', 'mexiletine_cyp1a2', 'Mexiletine', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-frovatriptan-mexiletine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-zolmitriptan', 'mexiletine_cyp1a2', 'Mexiletine', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-melatonin-mexiletine_cyp1a2', 'mexiletine_cyp1a2', 'Mexiletine', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-tasimelteon', 'mexiletine_cyp1a2', 'Mexiletine', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-mexiletine_cyp1a2-pirfenidone', 'mexiletine_cyp1a2', 'Mexiletine', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'moderate', 'established',
    'Mexiletine is a moderate CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Mexiletine and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Mexiletine is a moderate CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-theophylline', 'cimetidine_cyp1a2', 'Cimetidine', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-cimetidine_cyp1a2', 'cimetidine_cyp1a2', 'Cimetidine', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-clozapine_cyp1a2', 'cimetidine_cyp1a2', 'Cimetidine', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-olanzapine_cyp1a2', 'cimetidine_cyp1a2', 'Cimetidine', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-duloxetine_cyp1a2', 'cimetidine_cyp1a2', 'Cimetidine', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-ropinirole', 'cimetidine_cyp1a2', 'Cimetidine', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-ramelteon', 'cimetidine_cyp1a2', 'Cimetidine', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-tizanidine', 'cimetidine_cyp1a2', 'Cimetidine', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-frovatriptan', 'cimetidine_cyp1a2', 'Cimetidine', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-zolmitriptan', 'cimetidine_cyp1a2', 'Cimetidine', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-melatonin', 'cimetidine_cyp1a2', 'Cimetidine', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-tasimelteon', 'cimetidine_cyp1a2', 'Cimetidine', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-cimetidine_cyp1a2-pirfenidone', 'cimetidine_cyp1a2', 'Cimetidine', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'minor', 'probable',
    'Cimetidine is a weak CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'B', 0.85,
    'FDA_LABEL', 'Cimetidine and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Cimetidine is a weak CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'B', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-theophylline-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'theophylline', 'Theophylline',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate',
    'Increased Theophylline plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Theophylline toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Theophylline FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Theophylline is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-caffeine-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'caffeine', 'Caffeine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate',
    'Increased Caffeine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Caffeine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Caffeine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Caffeine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-clozapine_cyp1a2-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'clozapine_cyp1a2', 'Clozapine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate',
    'Increased Clozapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Clozapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Clozapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Clozapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-olanzapine_cyp1a2-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'olanzapine_cyp1a2', 'Olanzapine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate',
    'Increased Olanzapine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Olanzapine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Olanzapine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Olanzapine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-duloxetine_cyp1a2-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'duloxetine_cyp1a2', 'Duloxetine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate',
    'Increased Duloxetine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Duloxetine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Duloxetine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Duloxetine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ropinirole-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'ropinirole', 'Ropinirole',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate',
    'Increased Ropinirole plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ropinirole toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Ropinirole FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Ropinirole is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ramelteon-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'ramelteon', 'Ramelteon',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate',
    'Increased Ramelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Ramelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Ramelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Ramelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ticlopidine_cyp1a2-tizanidine', 'ticlopidine_cyp1a2', 'Ticlopidine', 'tizanidine', 'Tizanidine',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate',
    'Increased Tizanidine plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tizanidine toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Tizanidine FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Tizanidine is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-frovatriptan-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'frovatriptan', 'Frovatriptan',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate',
    'Increased Frovatriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Frovatriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Frovatriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Frovatriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-ticlopidine_cyp1a2-zolmitriptan', 'ticlopidine_cyp1a2', 'Ticlopidine', 'zolmitriptan', 'Zolmitriptan',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate',
    'Increased Zolmitriptan plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Zolmitriptan toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Zolmitriptan FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Zolmitriptan is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-melatonin-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'melatonin', 'Melatonin',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate',
    'Increased Melatonin plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Melatonin toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Melatonin FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Melatonin is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-tasimelteon-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'tasimelteon', 'Tasimelteon',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate',
    'Increased Tasimelteon plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Tasimelteon toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Tasimelteon FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Tasimelteon is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

INSERT INTO drug_interactions (
    interaction_id, drug_a_code, drug_a_name, drug_b_code, drug_b_name,
    interaction_type, severity, evidence_level, mechanism, clinical_effect,
    management_strategy, time_to_onset, documentation_level, active,
    dataset_version, evidence, confidence,
    gov_regulatory_authority, gov_regulatory_document, gov_regulatory_url, gov_regulatory_jurisdiction,
    gov_pharmacology_authority, gov_mechanism_evidence, gov_cyp_pathway,
    gov_clinical_authority, gov_severity_source, gov_management_source,
    gov_evidence_grade, gov_last_reviewed_date
) VALUES (
    'cyp1a2_interaction-pirfenidone-ticlopidine_cyp1a2', 'ticlopidine_cyp1a2', 'Ticlopidine', 'pirfenidone', 'Pirfenidone',
    'cyp1a2_interaction', 'moderate', 'established',
    'Ticlopidine is a moderate CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate',
    'Increased Pirfenidone plasma levels due to reduced CYP1A2 metabolism; potential for toxicity',
    'Monitor for Pirfenidone toxicity; consider dose reduction or alternative',
    'delayed', 'good', true,
    '2025Q3.matrix_gen', 'A', 0.85,
    'FDA_LABEL', 'Ticlopidine and Pirfenidone FDA Labels', 'https://dailymed.nlm.nih.gov', 'US',
    'DRUGBANK', 'Ticlopidine is a moderate CYP1A2 inhibitor; Pirfenidone is a CYP1A2 substrate', NULL,
    'LEXICOMP', 'DRUGBANK Classification', 'Clinical Guidelines',
    'A', CURRENT_TIMESTAMP
) ON CONFLICT (interaction_id) DO NOTHING;

COMMIT;

-- Verification: SELECT COUNT(*) FROM drug_interactions WHERE category LIKE '%cyp%';